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ABSTRACT 
A lyophilized polymeric wafer system was formulated for the provision of rapid 
drug release in the oramucosal region. Lyophilization produced a porous sponge-
like matrix which allowed simulated saliva to be rapidly imbibed into the 
hydrophilic structure. This surge of simulated saliva resulted in rapid 
disintegration of the wafer.  
 
Hydroxypropyl cellulose (HPC) was selected as the polymeric platform based on 
its low gelation potential. Other excipients incorporated into the system were 
lactose and mannitol as diluents, and glycine as a collapse protectant. A Face 
Centred Central Composite Design was chosen to establish the significant effects 
of the independent formulation variables on the physicochemical and 
physicomechanical properties of the wafer. The formulation variables investigated 
were, HPC concentration, type of diluent (lactose, mannitol or mixture), 
concentration of diluent, quantity of glycine and fill volume. An analysis of these 
variables elucidated the influential factors that may be controlled to form an ‘ideal’ 
wafer. The concentration of HPC significantly affected the disintegration rate 
(p=0.003), influx of simulated saliva (p=0.011) and friability (p=0.023). The 
quantity of diluent present in the system also had significant effect on matrix 
tolerance (p=0.029) and friability (p=0.032).  
 
Statistical optimization was undertaken using stepwise forward and backward 
regression, and Artificial Neural Networks to predict the ideal combination of the 
independent variables that would produce an ideal formulation. This wafer was 
required to produce a matrix disintegration of 3.33%/s, friability of 0.1% loss and 
maximum matrix resilience. Formulations manufactured with and without model 
drug, diphenhydramine hydrochloride, reflected no significant differences in their 
physicomechanical and physicochemical properties.  
 
In an attempt to expand the scope of this technology, a preliminary investigation 
was undertaken to develop a prolonged release wafer system. This was 
successfully achieved trough the application of crosslinking technology. It was 
possible to achieve drug released over a period of 6 hours.  
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Chapter 1      Introduction 
 
1.1 Background 
To achieve optimal drug therapy, one must ensure that patients receive the 
correct medication, at the right dosage, and at the most convenient dosing 
interval (Danckwerts, 2003). One of the major factors resulting in suboptimal 
therapeutic outcome is a lack of patient compliance, often due to inconvenient 
dosing systems or regimens (Goldberg et al., 1998; Playle and Keeley, 1998). 
Among the various routes of drug delivery, the oral route continues to be the 
most preferred mainly due to ease, convenience, safety and lower costs 
associated with drug administration. Furthermore, the pharmaceutical industry 
favours the formulation of orally administered tablets, due to the relative ease of 
production (Bredenberg et al., 2003). 
 
Peroral application of drugs also has various limitations such as slow onset of 
action, and in many cases, incomplete and erratic absorption. This may be the 
result of hepatic first-pass metabolism and degradation by the gastrointestinal 
enzymes, acidic pH and/or microbial flora. Such events often lead to a significant 
reduction in the oral drug bioavailability. Patient acceptance may be a problem, 
particularly with children and geriatrics experiencing problems with swallowing 
tablets. 
 
This study proposes to design an oral wafer system using the process of 
lyophilisation, for the rapid delivery of drugs on application to the oramucosa. The 
proposed wafer will dissolve in the sublingual region of the oral cavity within 30 
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seconds. This system aims to omit the rate limiting disintegration step of 
conventional tablets. The rapid disintegration of the system would also overcome 
problems experienced by patients who have difficulty swallowing tablets. 
 
Commercially available lyophilised products that currently dominate the market 
include: 
 Zydis® (R.P. Scherer; Basking Ridge, New Jersey, USA). The drug is 
physically trapped in a matrix consisting of a water soluble mixture of 
saccharide and gelatine. This is freeze-dried, leading to a product that 
dissolves rapidly when placed in the mouth. Drug candidates for this 
system would be chemically stable and water insoluble, having a small 
particle size, with a dose limited to 60mg. Large drug particles may 
sediment during the lyophilisation process (Seager, 1998); 
 Lyoc® (Farmalyoc; Laboratoire L. Lefon. Maisons-Alfort, France). An oil-in-
water emulsion is placed directly into the blister alveolus and subjected to 
lyophilisation. The emulsion is thick and paste-like containing the active as 
bulk or coated microparticles. A porous product is formed. This system 
can accommodate a high quantity of drug (Dobetti, 2001); and 
 Quicksolv® (Janssen Pharmaceutica, Beerse, Belgium). This tablet is in a 
porous solid form obtained by freeze-drying an aqueous dispersion or 
solution of the active-containing matrix. The matrix is then dried by 
removing the water using an excess of alcohol. Drugs compatible with this 
system are limited to those with a low dose and that are insoluble in the 
extraction solvent (Gole et al., 1990).  
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1.2 Technology Applied In This Study 
To achieve a rapidly dissolving wafer system, solubilised hydrophilic polymer 
combinations containing excipients either with or without drug will be moulded 
into small slabs through a lyophilisation process. Based on selection of 
appropriate polymer and/or excipient combinations the lyophilised system will be 
produced. Inherent in the lyophilisation process is the sublimation of water from 
the polymeric matrix which results in a highly porous, sponge-like polymeric 
network having a cylindrically planar geometry. On exposure of this system to the 
mucosa, saliva and mucus is spontaneously imbibed, the occurrence of which 
promotes rapid hydration and dissolution. Freeze-dried products, which are 
porous, lead to a high hydration capacity, and also tends to release their contents 
faster than products dried by other methods (Shojaei, 1998a).  
 
The preliminary studies investigating the modification of the wafer technology to 
provide prolonged release wafer systems will utilise the crosslinking of a polymer 
network in order to reduce drug diffusion. 
 
1.3 Advantages of Present Study 
The main advantages of the wafer system over conventional buccal/sublingual 
delivery systems such as tablets and liquid-filled softgels include: 
 Absence of matrix compression, thereby bypassing any deleterious 
phenomena associated with such manufacturing techniques, namely 
polymorphism, melting, degradation and crystalline/amorphous phase 
transitions. Peptides and proteins in particular are susceptible to 
destruction during consolidation processes and thus application of the 
proposed wafer system may avoid such denaturation. 
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 Inherent viscosity and release potential of selected hydrophilic polymer 
matrices may be easily modified through control of the rate and degree of 
sublimation.  This would allow for the modification of matrix porosity which 
in turn would modulate fluid influx rate and hence drug diffusion rate.  
Thus, changes in the drug release profile may be induced without the 
need for specialised excipients. The availability of such choice in 
formulation development has a major impact on the provision of a cost-
effective and thereby widely accessible delivery system.  
 
1.4 Motivation for Study 
Currently, the most popular commercially available rapidly dissolving lyophilised 
drug delivery system is Zydis®. The basic structure of the system is composed of 
gelatine. When gelatine is used in the production of rapid disintegrating dosage 
forms, it is necessary to heat the solution in order to effect solution. This heating 
step increases processing times and incurs heating costs. Conventional 
processing can require holding times of up to 48 hours. It has been observed that 
over this time the viscosity of the gelatine-based mixture can increase, leading to 
processing difficulties. Another known problem associated with gelatine-based 
fast dissolving dosage forms is the lack of homogeneity and sedimentation of the 
liquid mix during holding periods, as some mixtures incorporate the active 
substance as suspended particles.  
 
A novel feature of this study is that it provides the possibility of eliminating 
gelatine from fast dispersing dosage forms. Hydrophilic polymers may be used as 
the primary structure-forming agent to form a physically robust matrix while 
maintaining the desired rapid dispersion characteristics of the product. By the 
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careful selection of an appropriate hydrophilic polymer it is possible to obtain 
particularly desirable properties of cold water solubility, no change in solution 
viscosity with time and improved stability and physical strength of the delivery 
system. 
 
1.5 Objectives of Present Study 
With the above in mind, the following objectives were outlined for this study to: 
1. Conduct extensive preformulation studies to identify suitable excipients, 
establish appropriate lower and upper levels of concentration for a range 
of polymers and excipients and design preliminary native wafer platforms; 
2. Optimise of the lyophilisation cycle for the development of these wafer 
platforms that demonstrate rapid polymeric dissolution; 
3. Configure an Experimental Design strategy, namely the quadratic Face 
Centred Central Composite Design to systematically combine and test the 
candidate polymer and excipients for the production of wafer matrices; 
4. Assess the physicochemical properties of the wafers, specifically the 
disintegration rate, friability and chemical interactions as a result of 
lyophilisation; 
5. Gauge the physicomechanical (stress-strain) properties of the wafer 
matrix namely the yield value, tolerance, energy, resilience and Brinell 
Hardness Number; 
6. Mathematically optimise the derived physicochemical and 
physicomechanical properties using the data generated from the Face 
Centred Central Composite Design using solver technology® and Artificial 
Neural algorithms; and 
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7. Undertake a preliminary investigation into the possible modification of 
wafer technology to produce a prolong release system. 
1.6 Overview of This Study 
Chapter One 
The first chapter of this dissertation provides the introduction and rationale for the 
study. The introduction briefly describes the oral route as a site for drug delivery 
and provides a debate over advantages and limitations. The properties and 
manufacturing techniques of currently available lyophilised oral tablets are briefly 
outlined. This chapter finally outlines the approach, methodology and advantages 
of this study.  
 
Chapter Two 
The second chapter provides an insight into the background of the principles 
employed in this study. The utilisation of polymers for biomedical and drug 
delivery applications are outlined. This is followed by a description of the 
oramucosa as a site for drug delivery encompassing its anatomy, physiology and 
pros and cons of using this region. A concise description of commercially-
available intraoral dosage systems is undertaken. The key principles involved in 
the fundamental technique of lyophilisation utilised in the preparation of the 
intraoral system, are discussed. In anticipation of the problems associated with 
poor physical strength of lyophilised products, the concepts governing stress-
strain analysis conducted in this study are examined.  
 
Chapter Three 
To allow for an efficient and structured approach to experimentation, a statistical 
design was employed. Chapter three outlines the theory of the Design of 
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Experiments and highlights the various quadratic Response Surface Methods 
available. A motivation is provided for the use of the Face Centred Central 
Composite Design (CCF) in this study.  
 
Chapter Four 
The fourth chapter of this study describes the development of a lyophilised wafer 
system. Since it is critical that the wafer disintegrates rapidly on application to the 
sublingual region, it was essential that an appropriate polymer was selected. 
Once a suitable polymer was identified, other excipients and formulation 
variables were subsequently chosen. The upper and lower limits of the variables 
determined were used to generate the CCF used in this study. 
 
Chapter Five 
Chapter five includes the evaluation of the CCF with regard to the 
physicochemical and physicomechanical responses of the lyophilised wafer 
matrices. This includes the investigation of disintegration profiles; rate of influx of 
simulated saliva into the matrix; friability; matrix yield value; matrix tolerance; 
matrix absorption energy; matrix resilience; and Brinell Hardness Number. 
 
Chapter Six 
In addition to the responses measured for the CCF, the qualitative study, 
Differential Scanning Calorimetry (DSC) was conducted on the wafers and native 
excipients to analyse the effect of lyophilisation on the wafer constituents. This is 
elaborated in detail in chapter six.  
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 Chapter Seven 
The pinnacle of this study is reached in chapter seven which involves 
optimisation of the wafer system. The fundamental properties of the matrix 
(disintegration rate, friability and resilience), were optimised using multiple 
regression and Artificial Neural Networks (ANN). The model drug 
diphenhydramine hydrochloride was incorporated into the optimised formulation 
to establish the effect of active ingredient on the matrix.  
 
Chapter Eight 
Diphenhydramine hydrochloride was maintained as the model drug in the 
preliminary studies aimed at modifying the wafer technology to produce a 
prolonged release wafer system. The modification outlined in chapter eight 
involved incorporating cross linking technology to the existing system to ensure 
the release of active ingredient over a sustained period.  
 
Chapter Nine 
The final chapter of this study discusses the overall suitability of the wafer 
developed for oramucosal application. Recommendations are made for the 
improvement of such a delivery system for future studies.  
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Chapter 2      Polymers and Oramucosal Delivery Systems 
 
2.1  Introduction 
Polymers form an integral component of products manufactured for medical and 
pharmaceutical applications. Polymeric materials are amenable to various uses 
due to their mechanical characteristics, chemical stability, light weight and 
uncomplicated design possibilities. The first polymers to be utilised in biomedical 
applications were the widely used commodity polymers (e.g. polyethylene, 
polypropylene and polystyrene) (Streubel et al., 2003, Iconomopoulou et al., 
2005, Palakurthi et al., 2005). These polymers were not developed at the onset 
with biocompatibility as a concern. During recent years many specialty polymers 
have been developed to meet the complicated demands for medical 
development, the optimisation of structure-property correlations and ultimately 
clinical use (Brocchini, 2001, Kholodovych et al., 2004). Polymers are applied to 
a large number of medical applications such as medical supplies, support 
replacement of malfunctioning body parts, and as drug reservoirs to provide a 
local therapeutic effect. A few examples of these polymers are listed in Table 2.1. 
 
In addition to the applications listed in Table 2.1, polymeric materials have found 
extensive use in the design of drug delivery systems. 
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Table 2.1 Polymers for specific biomedical applications 
Non-Degradable Polymer Biomedical Application 
Polyamides 
Polycarbonates 
Polyesters 
Poly(vinyl chloride) 
Polyurethanes 
Silicones 
Biodegradable Polymer 
Polylactic/glycolic acid 
Polyorthoesters 
Cyanoacrylates 
Polylactic acid 
Sutures 
Device housing 
Vascular Grafts 
Tubing and Blood bags 
Tubing and Coatings 
Tubing and Soft tissue reconstruction 
Biomedical Application 
Sutures 
Bone plates 
Wound closure 
Tendon repair 
 
2.2 Application of Polymers in Drug Delivery  
Polymer macromolecules are a highly versatile and diverse group, many of which 
have been selected for specific applications in the field of drug delivery. Many of 
them play a role in solubilisation, nanoparticle formulations, surface modification 
and as macromolecular drug carriers (Khomyakov et al., 1965, Moghimi and 
Hunter, 2001, Tosi et al., 2005). The use of polymers in drug delivery continues 
to increase as clinical results show therapeutic benefits, novel applications are 
discovered, and sources of polymers and their derivatives become more 
accessible. Technology improvement of tablets such as the ability to control drug 
release profiles has been demonstrated by scientists using polymers as coating 
systems (Tarvainen et al., 2004) or incorporating the polymers as tablet 
excipients (Mahaguna et al., 2003; Toti and Aminabhavi, 2004).  
 
Research into ‘intelligent’ polymers has boomed during the twenty-first century, in 
response to the growing need for site-specific drug delivery systems. Targeted 
drug delivery offers specific advantages over conventional dosage systems, such 
as a reduction in the frequency and severity of side effects. Attention has been 
given to site-specific drug release in the gastrointestinal tract (GIT), ocular cavity, 
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and malignant cells, enabling disease conditions to be treated from the affected 
site (Pillay and Fassihi, 1999 a,b; Gharat et al., 2001; Rudolph et al., 2001; 
Vandamme, 2002). The mechanisms utilised to provide site-specific delivery 
varies. pH sensitive systems allow dissolution of the device to be in a specified 
area of the GIT (Pillay and Fassihi, 1999a). In a study by Kono (2001), liposomes 
were developed whereby the contents, release behaviour, surface properties and 
affinity to cell surface could be controlled in a temperature-dependent manner. In 
another study by Piskin (2004), the delivery system responded to environmental 
stimulus such as changes in pH, ionic strength, light, electrical and magnetic 
field. 
 
Concern was expressed by Pardridge (2002) about the use of nanoparticles 
containing detergents for site-specific drug delivery. Detergents such as cholic 
acid or polysorbate-80 are added to prevent aggregation and stabilise 
nanoparticles. However these detergents may be toxic in vivo. Polysorbate-80 
causes disruption of the blood-brain barrier at a concentration as low as 3mg/kg 
(Azmin et al., 1985). On the other hand, Olivier and co-workers (1999) suggested 
that nanoparticles may mediate drug delivery to the brain just by temporarily 
disrupting the blood-brain barrier. 
 
From the studies above, the significant impact of polymer technology in drug 
delivery systems can be clearly seen. The present study is specifically aimed at 
formulating a polymeric-based mucosal delivery system and, hence, the 
associated principles will be discussed in detail. 
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2.3 Transmucosal Drug Delivery 
Due to the limitations of conventional oral systems discussed in Chapter 1, 
transmucosal routes of drug delivery (i.e. the mucosal linings of the nasal, rectal, 
vaginal, ocular and oral cavity) may offer distinct advantages over peroral 
administration for systemic drug delivery. Some of the reasons include: 
 The drug is not subjected to the destructive acidic environment of the 
stomach; 
 Therapeutic serum concentrations of some drugs can be achieved more 
rapidly; and 
 The drug enters the general circulation without first passing through the 
liver. 
Combinations of the above factors lead to a higher bioavailability (Bredenberg, 
2003). In general, these mucosal surfaces are rich in blood supply, providing a 
means for rapid drug transport to the systemic circulation. Despite the abundance 
of mucosal areas amenable to drug application and delivery, the oral cavity still 
provides the most appeal to patients based on its convenience. 
 
2.3.1  Oramucosal Drug Delivery 
In addition to greater patient compliance, the oramucosal route offers distinct 
advantages over other mucosal drug delivery sites. There are no known adverse 
physiological effects, and the oramucosa is less vulnerable to damage or irritation 
than the nasal mucosa (Danckwerts, 2003). 
 
The mouth is lined with a mucous membrane which is capable of serving as a 
site for the absorption of drugs. The oral mucosa is robust and shows short 
recovery times after stress or damage (Rathbone and Hadgraft, 1991; de Vries et 
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al.,1991; Squier, 1991). Also the absence of Langerhans cells provides a high 
level of tolerance to potential allergens (Bodde et al., 1990). Furthermore, drug 
absorption is facilitated by the continual washing action of saliva (0.5-2 litres per 
day) over the mucosal surface.  This route also allows for excellent accessibility 
and easy removal of the system in case of an adverse drug reaction (Lee, 2002). 
These factors consequently support the oramucosal cavity as a highly feasible 
and rational site for systemic drug delivery.  
 
2.3.1.1 Anatomic and Physiological Considerations 
Four sites within the buccal cavity have been used for drug administration. The 
four regions have varying permeability, which plays a role in the absorption of 
drugs across the oral mucosa. As seen in  
 
 
Figure 2.1, the four key areas are the buccal cavity, the lingual area, the palate 
and gingival region. The most commonly used sites for drug administration of the 
four mentioned above is the sublingual and buccal route. Using the sublingual 
route, the medicament is placed under the tongue, usually in the form of a rapidly 
dissolving tablet. The anatomic site for drug administration between the cheek 
and gingival is known as the buccal mucosa. 
 
The oral mucosa is composed of three layers (Figure 2.2). The first layer is the 
stratified squamous epithelium; underneath this layer lies the basement 
membrane. The basement membrane overlies the lamina propria and 
submucosa. 
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Figure 2.1 Mucosal regions of the mouth (Danckwerts, 2003) 
 
The constitution of the epithelium within the different sites of the oral cavity shows 
dissimilarity. The gingival and hard palate are exposed to mechanical stress 
during eating, hence the epidermis is keratinised in a similar manner as the skin. 
The epithelium in the soft palate, buccal and sublingual area is not keratinised, 
therefore not containing ceramides and acylceramides which are associated with 
providing a barrier function (Squier, 1991; Wertz and Squier 1991; Harris and 
Robinson, 1992). The mucosa of the buccal and sublingual region have only 
small amounts of ceramide, and is thus more permeable when compared to other 
regions of the oral cavity (Shojaei, 1998b).  
 
The presence of membrane coating granules (MCGs) accounts for the 
differences in permeability amongst the various regions of the oral mucosa. 
When cells go through differentiation from basal to flattened keratinous cells, 
MCGs are formed. At the apical cell surface, MCGs merge with the plasma 
membrane and their contents are discharged into the intercellular spaces. This 
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occurs mainly in the upper one-third of the epithelium. MCGs are present in both 
keratinised and nonkeratinised epithelia, however their composition is different. 
On the other hand, non-keratinised epithelium contains MCGs that are 
nonlamellar and include cholesterol, cholesterol esters and glycospingolipids 
(Wertz and Squier, 1991). 
 
(a) (b) 
Mucus layer
Parakeratinise
Stratum basale 
Basal 
Lamina propria 
Epithelium 
Figure 2.2 Composition of the layers of mucosal epithelium: (a) keratinised; and 
(b) nonkeratinised (Danckwerts, 2003) 
 
A layer of mucus is present on the surface of the epithelial layer of cells. This 
plays a major role in cell-to-cell adhesion, oral lubrication, as well as 
mucoadhesion of mucoadhesive drug delivery systems (Peppas and Buri, 1985). 
A major feature in the environment of the oral cavity is the presence of saliva. 
The salivary glands produce saliva, responsible for protecting the soft tissues 
from abrasion during the mastication of food. Saliva plays an essential role in 
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facilitating the disintegration of quick-disintegrating drug delivery systems 
(Rathbone et al., 1994). 
 
The buccal and sublingual regions are different from each other in terms of 
anatomy, permeability to drug, and their ability to retain a drug delivery system for 
a desired duration. Although the buccal mucosa is less permeable than the 
sublingual mucosa and does not yield a rapid onset of action as seen with 
sublingual delivery, mucosa of the buccal area has an expanse of smooth and 
relatively immobile surface, which is suitable for placement of a retentive system. 
For buccal drug delivery, adhesion to the oral mucosa permits not only the 
intimacy of contact and the possibility of improved drug absorption, but also the 
ability to achieve an optimum residence time at the site of administration (Martin 
et al., 2002). These characteristics make the buccal mucosa a more appropriate 
site for prolonged systemic delivery of drugs.  
 
The sublingual route is however more suitable for delivery systems formulated 
either as rapidly disintegrating matrices or softgels. These systems create a 
highly significant drug concentration in the sublingual region prior to systemic 
absorption across the mucosa. 
 
2.3.1.2 Absorption of Drugs 
In general, drugs penetrate the mucous membrane by simple diffusion via 
paracellular and transcellular routes and are carried in the blood, which richly 
supplies the salivary glands and their ducts, into the systemic circulation via the 
jugular vein (Martin et al., 2002). Figure 2.3 depicts the pathway of drug 
absorption through the sublingual route.  
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Substances that can be administered by this route have limitations. The type of 
drugs absorbed via this route is dependent on the pH-partition hypothesis, pKa-
partition theory and the lipid-water partition (Martin, 1993). The absorption of 
hydrophobic drug substances in the GIT is aided by the presence of bile acids. 
These are not present in the mouth and may compromise the availability of such 
drugs.  
 
Figure 2.3 Absorption of drugs via the sublingual route (Adapted from http:// 
abdellab.sunderland.ac.uk) 
 
2.3.1.3 Problems Associated with Buccal and Sublingual Systems 
Similar to other mucosal membranes, the buccal mucosa as a site for drug 
delivery also has limitations. One of the major disadvantages associated with 
buccal drug delivery is the low flux that exists across the membrane, which may 
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result in incomplete transmucosal drug diffusion. In this respect, various 
compounds such as bile salt surfactants and chelators have been investigated as 
penetration enhancers in order to increase the flux of drugs through the mucosa 
(Aungst et al., 1988; Aungst and Rogers, 1988; Aungst and Rogers, 1989). 
 
Other than the low flux associated with buccal mucosal delivery, a major 
limitation of the buccal route of administration is the lack of dosage form retention 
at the site of absorption. Consequently, hydrophilic polymers capable of gelation 
and swelling may be employed in the design of buccal drug delivery systems to 
enhance bioadhesiveness.  Polymers may form hydrogen bonds with the 
mucosal surface and thus produce bioadhesive properties (Shojaei et al., 1998 
a,b). 
 
Although the oramucosal route is favoured due to the ease of administration, 
sublingual preparations may pose discomfort, due to the unpleasant feeling and 
may cause local irritation to the membranes. 
  
Anatomical inconsistency in membranes such as the thickness and level of 
keratinisation may cause inter-patient variability in the level of bioavailability.  
 
2.4 Drug Delivery Systems for Intraoral Application 
Intraoral drug delivery systems are intended for the movement of drug through 
the oral mucosa. These systems generally fall into one of the four broad 
categories: mucoadhesive buccal patches and tablets, quick disintegrating solid 
dosage forms, solid intraoral delivery systems and aerosol intraoral drug delivery 
systems. 
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Figure 2.4 Classification of intraoral drug delivery systems 
 
2.4.1  Intraoral Mucoadhesive Systems 
2.4.1.1 Mucoadhesive Patches 
The distinct advantage of mucoadhesive patches and tablets is that they provide 
a longer period over which to deliver the drug to and through the buccal mucosa. 
In contrast to the rapidly-disintegrating systems, they are not adversely affected 
by the risk of swallowing a large portion of the dose with saliva. In addition, 
mucoadhesive systems allow for controlled release of the drug to be delivered 
through the oral mucosa in the same fashion that transdermal systems do. Much 
research has been conducted on mucoadhesive polymers and therapeutic 
systems, however not many have reached commercial production. Effective 
bioadhesion and patient compliance still remain areas of concern (de Vries, 
1991). The majority of mucoadhesive patches and tablets are formulated either 
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as solvent-cast mucoadhesive polymer discs or directly compressible flat-faced 
tablets of 1-3mm thickness.  
 
2.4.1.2 Mucoadhesive Tablets 
From an economic perspective, mucoadhesive tablets have the advantage that 
the technology used to produce them is usually the same process as 
compression technology used to produce conventional tablets. This makes them 
popular from a manufacturing point of view, reducing the number of equipment 
needed. A major limitation however is that a large portion of active drug is 
swallowed by the patient, which precludes drugs that are slowly absorbed 
through the oral mucosa. For this reason, drugs susceptible to instability or 
metabolism in the GIT are not compatible with this delivery system.  
 
2.4.1.3 Mucoadhesive Liquids 
A vast number of oral rinse formulations are available on the market.  This may 
be suitable for oral hygiene applications, however for a drug delivery system, a 
longer contact time with the oral mucosa is desirable. Access Pharmaceuticals 
(Dallas, USA) has recently provided a solution to this problem. Their 
MucoAdhesive Liquid technology® provides an extended coating of the oral 
mucosa, due to the pseudoplastic and mucoadhesive nature of the liquid, 
allowing active ingredients to be present over extended periods of time.  
 
2.4.2 Solid Intraoral Drug Delivery Systems 
In the past, local mouth diseases and sore throats have been successfully treated 
using medicated oral lozenges. Most are manufactured as candy-type lozenges 
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or compressed tablets that are sucked by the patient. Previously, drugs with few 
systemic adverse effects were used with this type of system. More recently 
however, more potent drugs, with lower doses have been included into lozenges 
for the quicker intraoral absorption properties (Spijkervet et al., 1991; Okuno et 
al., 1997, Schachtel et al., 2002) 
 
2.4.3  Aerosol Intraoral Drug Delivery Systems 
In the search to develop alternative routes for the administration of insulin, an 
aerosol system was developed. Oralin® (Generex Biotechnology, Toronto, 
Ontario, Canada) delivers accurate doses into the mouth by use of a metered-
dose aerosol. This aerosol formulation is rapidly absorbed through the buccal 
mucosa and oropharyngeal regions (Modi et al., 2002). Plasma insulin levels 
were sufficient to control postprandial glucose increases in diabetic patients.   
 
The direct absorption of nitroglycerin in the form of an aerosol provides a faster 
onset of action as compared to the tablet (Reisin et al., 1988; Wight et al., 1992). 
 
2.4.4 Quick-Disintegrating Intraoral Drug Delivery Systems 
 Some of the other terms used to describe this class of delivery system include, 
fast-dissolve, quick-dissolve, rapid melting and quick-disintegrating. 
Disintegration describes the system slightly more accurately than dissolving. 
Systems that undergo rapid disintegration in the oral cavity are predominantly 
intended for the patient to swallow the bioactive agents; absorption will occur in 
the GIT.  
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Quick-disintegrating intraoral drug delivery systems can be made by a number of 
processes including, direct compression, wet granulation and freeze-drying 
(lyophilisation).  
 
2.4.4.1 Rapid-Melting Tablets 
Quick-disintegrating intraoral tablets have also been created by using lipid waxy 
binders that melt at body temperature. Cherukuri (2000) patented a novel rapid-
melt, semisolid, moulded composition including at least one melted wax binder, a 
salivating agent, diluent material, a slipping agent and an active ingredient. On 
the application of pressure, the composition becomes liquid. Hence once in the 
patient’s mouth, application of pressure by the tongue, converts the semisolid into 
a liquid carrying the active substance. The final tablets may be coated to prevent 
melting on storage in warmer climates. 
 
2.4.4.2 Disintegrating Films 
Mucoadhesive and quick-disintegrating films have been patented by Zerbe and 
co-workers (1999). This delivery system has been used for pharmaceutical and 
cosmetic applications. Films are water-soluble with instant wettability, and 
immediate softening on application to the mucosal tissue. The dry film has 
adequate tensile strength to undergo cutting, slitting and packing operations. 
 
2.4.4.3 Effervescent Tablets 
Like conventional effervescent tablets that dissolve in water, OraSolv®, produced 
by Cima Labs Inc. (Eden Prairie, Minnesota, USA) is activated by saliva. On 
insertion into the patient’s mouth, disintegration occurs rapidly without voluntary 
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action by the patient. The disintegrated tablet is swallowed and absorbed via the 
GIT. Due to the specialised packaging requirements, PakSolv®, Cima’s 
packaging system and DuraSolv®, a more robust dosage form has been created. 
DuraSolv® can be packaged using conventional methods such as foil pouches or 
bottles. Cima Labs Inc. developed an effervescent tablet, OraVescent®, 
containing a pH-adjusting substance to facilitate the intraoral absorption of drugs.  
 
2.4.4.4 Open Matrix-Type Wafers and Tablets 
With the introduction of the Zydis® system (R.P. Scherer; Basking Ridge, New 
Jersey, USA) in the late 1970s, the concept of quick disintegrating drug delivery 
systems gained much attention. It was the first of this class of delivery systems to 
be manufactured on a large scale. It is a freeze-dried wafer made from various 
standard tablet adjuvants (Virley and Yarwood, 1990). The wafer essentially 
works on the principle of forming an open network containing the active 
ingredient. Figure 2.5 illustrates the Zydis® manufacturing process. The freeze-
dried tablet disintegrates within 2-3 seconds, releasing the active ingredient. The 
drug either forms a dispersion or dissolves in the saliva, which is then swallowed 
and absorbed via the GIT.   
 
Slurry poured
into blister 
mould 
Freeze-dried
in mould 
Product 
sealed 
Figure 2.5 Production of the Zydis® lyophilised wafer (Danckwerts, 2003) 
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The WOWTab® (With-Out-Water tablet) has been produce by Yamanouchi 
Pharmaceutical Co. Ltd. (Tokyo, Japan). This tablet is manufactured using 
conventional granulating and compression. The rapid disintegration is attributed 
to the blending of a low and high moldability saccharide. The unique combination 
of saccharides provides sufficient mechanical strength as well as quick tablet 
disintegration.  
 
Fuisz Technology Ltd. (Chantily, Virginia, USA) developed the Flash Dose® 
tablet, which can dissolve in the patient’s mouth in less than 10 seconds. This 
has been achieved by the use of Shearform™ technology. The process involves a 
unique blend of sugars being placed in a fast spinning machine and subjected to 
flash heat. By this process, long cotton-like fibres called ‘floss’ are produced. The 
‘floss’ is then cured by subjecting it to specific environmental conditions that 
induce crystallisation, at this stage crystallisation modifiers may also be added. 
The matrix is then blended with coated or uncoated microspheres containing the 
active drug. The floss is compressed using standard tabletting equipment (Misra 
et al., 1999). Figure 2.6 illustrates the manufacturing process. 
 
Tablet is  
compressed 
Drug mixed 
with spun 
sugar 
granules
Sugar is spun,
treated, and cut
to granule size
Compact mass
Figure 2.6 Manufacturing process of Flash Dose® (Danckwerts, 2003) 
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Of the various open matrix-type wafers on the market, the Zydis® system remains 
the most popular, as a result making lyophilisation the most frequently used 
process for the manufacture of these systems. 
 
2.5 Lyophilisation 
The principle of lyophilisation is to remove water or solvent material through the 
process of sublimation. Sublimation is a method whereby a substance changes 
from a solid directly into vapour. Water will sublime from a solid (ice) to a gas 
(vapour) when the molecules have sufficient energy to be liberated but the 
conditions are not conducive for a liquid to form.  
 
There are two major factors that determine in which phase (solid, liquid or gas) a 
substance would exist, namely heat and atmospheric pressure. These 
parameters must be within a certain range for phase transitions to occur. Without 
these conditions, that phase of the substance cannot exist. The phase diagram 
below illustrates the necessary pressure and temperature conditions for different 
phases of water.  
 
Each line (OA, OB and OC) Figure 2.7 provides the conditions when two phases 
coexist but a change in temperature or pressure may cause the phases to 
abruptly change from one to the other. The ‘triple point’ is the intersection on the 
phase diagram where three phases, consisting of ice, liquid and vapour, coexist 
in equilibrium but change into each other given a change in temperature or 
pressure.  
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 Figure 2.7 Phase diagram of water (Martin, 1993) 
 
The ‘critical point‘ occurs when the properties of the two phases become 
indistinguishable from each other. The line between the gas and solid phase 
(OC) indicates the vapour pressure of the solid as it sublimes at different 
temperatures. The freeze-drying apparatus creates the conditions necessary for 
sublimation to occur. 
 
2.5.1 The Lyophilisation Process 
A typical instrument consists of a freeze-drying chamber with several shelves 
attached to heating units, a freezing coil connected to a refrigerator compressor, 
and a vacuum pump.  
 
The lyophilisation process consists of three stages: freezing, primary drying and 
secondary drying. During the freezing phase, the material is placed onto the 
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shelves when it is still unfrozen. The chamber is sealed to begin the process; the 
compressors lower the temperature in the chamber. The material is frozen to a 
solid, which on a molecular level, separates the water from everything around it. 
The initial crystal size depends on the relative contributions of nucleation and 
crystal growth of ice. A rapid nucleation and growth rate resulting from a large 
degree of supercooling leads to a number of small ice crystals. Small ice crystals 
produce pores in the final product with lower volume-surface area. 
 
Primary drying is accomplished by negative pressure, traditionally carried out at 
40 – 400 Torr. The heating units apply a small amount of heat to the shelves 
(ranging from -30 to +10˚C), causing the ice to change phase. Throughout this 
stage, the product is maintained in the solid state below the collapse temperature 
of the product in order to dry the product with retention of the structure 
established in the freezing step. The product temperature remains relatively 
constant and drying follows a pseudo steady-state rate with heat removal by 
sublimation at the same rate as the heat input supplied by the shelves.  
 
This is expressed thermodynamically in the form of an equation introduced by 
Pikal (1993) as: 
dt
dQ
dt
dmHS =×Δ         (Equation 2.1) 
Where:  
SHΔ  is the heat of sublimation; 
dt
dm  is the sublimation rate; and 
dt
dQ  is the rate of heat input. 
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The rate of sublimation can be expressed as:  
( )
( )SP
CO
RR
PP
dt
dm
+
−=        (Equation 2.2) 
Where: 
 (  is the thermodynamic driving force, P)
)
CO PP − 0 is the vapour pressure of ice in 
the frozen sample and Pc is the total pressure in the chamber; and 
( SP RR +  is the total resistance to sublimation, Rp is the product resistance and 
Rs is the resistance of the stopper of the vial. 
The rate of heat input can be expressed as:  
( PSVV TTKAdt
dQ −××= )
)
      (Equation 2.3)
Where:  
Av is the cross-sectional area of the vial; 
Kv is the heat transfer coefficient; and 
( PS TT −  is the heat difference between the shelf (Ts) and the product (Tp). 
 
The vapour pressure (Po) of the ice in the product increases exponentially with 
the temperature, so that an increase in product temperature will cause an 
increase in the rate of sublimation. The water vapour condenses onto the 
freezing coil in solid ice form. This continues for many hours, while the material 
gradually dries out. The gradual process is necessary as overheating the material 
can significantly change the composition and structure.  
 
At the end of primary drying, secondary drying will begin spontaneously. This 
occurs when unfrozen water is removed from the matrix. This may include a 
small amount of bound moisture removed by desorption. Initially the rate of water 
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loss is large, followed by a plateau beyond which further water removal is very 
slow (below ≈ 2%). The rate of water removal is controlled by the rate of diffusion 
of the solute/vapour interface and the subsequent evaporation.  
 
The resultant product is completely void of water, and may have a porous 
structure as a result of voids left where water was present (Craig et al., 1999; 
Bedu-Addo, 2004).  
 
2.5.2 Pharmaceutical Application of Lyophilisation 
Lyophilisation is used extensively and diversely in the pharmaceutical industry. It 
has been used to stabilise various pharmaceutical products, including vaccines, 
proteins and peptides, liposomes and small-chemical drug formulations 
(Mozhaev and Martinek, 1984; Colaco et al., 1992; Pikal et al., 1992 and Cleland 
et al., 2001).  
 
Furthermore, freeze-drying has been used as the principle process in the 
development of numerous drug delivery systems. The desired characteristics of 
lyophilisation (Bedu-Addo, 2004) that make this process attractive to the 
pharmaceutical industry include:  
 Long term stability; 
 Short reconstitution time; 
 Elegant cake appearance; 
 Maintenance of the dosage form characteristics upon reconstitution, 
including solution properties, conformation of proteins, and particle size 
distribution of suspensions; and 
 Isotonicity upon reconstitution. 
 29
Delivery systems using the process of freeze-drying include parenterals, 
suspensions, microspheres, eye applications and tablets (Mal et al., 1999; 
Ameye et al., 2002; Bouma et al., 2002; Donini et al., 2002; Kakish et al., 2002; 
Kim et al., 2004; and Suverkrup et al., 2004). 
 
Particular attention has been given to the use of lyophilisation in the preparation 
of parenterals containing anti-cancer agents. In a study by Bouma and co-
workers (2002) freeze-drying was used to increase the stability of NAMI-A, a 
novel antimetastatic ruthenium complex for at least one year. The shelf life of 
melphalan, an anti-neoplastic agent with poor aqueous solubility, was increased 
when lyophilised with specific excipients (Mal et al., 1999). 
 
The drug loading capacity of polymeric micelles containing taxane was increased 
by applying the lyophilisation process to a solution containing drug and an 
amphiphilic copolymer in a water/butanol mixture (Fournier et al., 2004). 
 
The freeze-drying of microspheres produces a product that is buoyant and thus 
has the ability to float on the gastric contents increasing the gastric retention time 
of the system (Whitehead et al., 2000; Kakish et al., 2002). 
 
The ophthalmic lyophilisate carrier system (OLCS) is novel for the delivery of 
pharmacologically active ingredients or other substances improving the structure 
of the tear film to the eye. A drop of lyophilisate containing the drug and bulk 
forming water-soluble or swelling excipients is attached to a flexible hydrophobic 
carrier (Suverkrup et al., 2004). 
 
 30
In addition to employing freeze-drying in the preparation of bioadhesive tablets 
(Ameye et al., 2001), lyophilised tablets are increasingly popular as rapidly 
disintegrating systems (fast-melting tablets). Despite the rapid dissolution and 
disintegration times of these systems, high cost of production, the limitation to low 
dose of water-soluble drugs and poor physical resistance still remain a problem. 
 
As a result of the poor physical strength of the rapidly disintegrating lyophilised 
systems, the physicomechanical properties of the wafers formulated in this study 
were extensively investigated. 
 
2.6 Physicomechanical Analysis 
In order to understand the impact of the mechanical properties of the wafer 
system on its physicochemical behaviour, textural profiling was undertaken. In 
general, mechanical characterisation of a material is an assessment to gain an 
understanding a of material’s reaction to stress and strain in relation to its 
deformation. Stress is defined as the force per unit area acting on a material and 
tending to change its dimensions. It is the ratio of force to the area over which it is 
applied. This differs from strain which is the percentage deformation of a body 
when subjected to a load. Strain can be manifested as tensile, compressive, 
shear or volumetric changes (Martin, 1993). 
 
The elastic theory describes deformation where the material rebounds to its 
original shape after the forces on it have been removed (Martin, 1993). Linear 
elasticity occurs when stress is directly proportional to strain in one dimension as 
described by Hooke’s Law:  
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δ= Eε          (Equation 2.4) 
Where: 
δ = Stress; 
E = Young’s modulus; and 
ε = Strain. 
 
Most materials deviate from Hooke’s law (Equation 2.4), by exhibiting both elastic 
as well as viscous-like behaviour.  These materials are termed viscoelastic 
substances. These materials responding to a deforming load, combine both 
viscous and elastic qualities. The relationship between stress and strain depends 
on time. 
Some phenomena associated with viscoelastic materials are: 
 If the stress is held constant, the strain increases with time; 
 If the strain is held constant, the stress decreases with time (relaxation); 
 The effective stiffness depends on the rate of application of the load; 
 If cyclic loading is applied, hysteresis occurs, leading to the dissipation of 
mechanical energy; 
 Acoustic waves experience attenuation; 
 Rebound of an object following an impact may be less than 100%; and 
 During rolling, frictional resistance occurs. 
 
Figure 2.8 shows the reaction of polymeric substances in terms of strain on the 
application of stress. 
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Figure 2.8 Stress-strain behavior of polymers 
 
2.6.1 Stress – Strain Behaviour of Polymers 
The moduli of elasticity for polymers range from 10MPa – 4GPa. The tensile 
strengths range from 10MPa – 100MPa, and elongation can be up to 100% in 
some cases. Mechanical properties of polymers are sensitive to the rate of 
deformation. Plastic deformation is defined by the interaction between crystalline 
and amorphous regions and is partially reversible.  
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 Figure 2.9 Stages of plastic deformation of semi-crystalline polymers 
 
As seen in Figure 2.9, the stages of plastic deformation of semi-crystalline 
polymers include:  
1. Elongation of amorphous tie chains; 
2. Tilting of lamellar crystallites towards the tensile axis; 
3. Separation of crystalline block segments; and 
4. Stretching of crystallites and amorphous regions along tensile axis. 
 
In polymers, energy elasticity represents the storage of energy resulting from the 
elastic straining of bond angles and lengths like springs from their equilibrium 
value. Entropy elasticity is caused by the decrease in entropy upon straining. In 
an unstressed state, the polymer molecules are free to adopt a number of 
random configurations, switching from one to another through rotation about 
bond angles. Under the application of tensile force, the molecules are stretched 
out, and fewer configurations are possible. It is therefore deduced that stretching 
decreases the entropy (Rosen, 1971).  
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2.6.2 Biomedical Applications of Mechanical Testing 
Compression tests are commonly used to assess products with biomedical 
applications. Compressive stress and strain are calculated and plotted as a 
stress-strain profile which is used to determine the elastic limit, proportional limit, 
yield point, yield strength and for some materials compressive strength. 
Practical applications include:  
 Orthopedic testing of raw materials, impact loading of joint components 
and simulation for the evaluation of fatigue and wear properties in vivo. 
Biomechanic studies relate to the human body in motion. This is essential 
in the design and manufacture of prosthetic and mobility aids (Lee et al., 
1999; Howard et al., 2002; Boylan et al., 2003 and Beingessnera et al., 
2003); 
 The relationship between the structure of a biomaterial (e.g. polymer) and 
its mechanical properties is assessed through mechanical testing and 
simulation. Commonly gel strength, elasticity and rupture force are 
measured (Jones et al., 1996; Park et al., 2001; Pillay and Danckwerts, 
2002); 
 Novel methods involving mechanical testing have also been developed to 
evaluate mucoadhesion and bioadhesion (Moss et al., 1999; Shojaei et 
al., 2000); 
 In relation to the quality control of medical devices, the material strength of 
catheters, surgical tubing and fittings are often determined using 
mechanical testing. Furthermore the tensile strength of bandages, medical 
gloves, sutures, stents and adhesives are measured (Meyer et al., 2003); 
and 
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 Mechanical profiling has been used in the analysis of various dosage 
forms such as patches and films, tablet coating, capsules, gels, 
suspensions, parenterals and pellets (Campbell et al., 1999; Pillay and 
Fassihi, 1999b; Repka and McGinity, 2000; Park and Munday, 2003; 
Allahhama et al., 2004). 
 
During this study, the energy of absorption, matrix yield value, matrix tolerance, 
matrix resilience and Brinell Hardness Number of the various formulations were 
assessed. 
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Chapter 3      Theoretical Framework for Design of Experiments 
 
3.1 Introduction 
To achieve the desired characteristics of a drug delivery system, it is necessary 
that we can identify factors that are influential to the properties of the formulation. 
During the preformulation stage, we deliberately change one or more process 
variables or factors, to determine the effect that the change may have on 
response variables. Design of Experiments (DOE) is an efficient statistical 
procedure for planning experiments so that the data obtained can be analysed to 
yield valid and objective conclusions. 
 
DOE begins with determining the objectives and selecting process factors of an 
experiment. An experimental design is the laying out of a detailed experimental 
plan prior to conducting the experimentation. This serves to minimise the number 
of trial experiments that need to be conducted to determine optimal conditions of 
variables for a response. An appropriately selected experimental design can 
maximise the amount of information that can be obtained from a given amount of 
experimental data. The levels of each factor range from high to low. 
 
Ensuring the successful choice and implementation of an experimental design 
lies primarily in clearly identifying the objectives of the experiment and 
determining the number of factors to be investigated. 
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3.1.1 Experimental Design Objectives 
3.1.1.1 Comparative Objective  
The primary goal of the experimentation is to draw a conclusion about one a-
priori factor amongst several other factors under investigation. Of interest is 
whether or not there is a significant change in the response for different levels of 
that factor. This is classified as a comparative problem, and a comparative design 
solution is required. 
 
3.1.1.2 Screening Objective 
 When the purpose of the experiment is to select the few important main effects 
from the many screening designs, main effects designs can be applied. This 
normally consists of trails run at the extreme lower and upper-bound level setting 
combinations of the variable study ranges. Screening designs enable researchers 
to select the best materials and equipment from the available alternatives.  
 
3.1.1.3 Response Surface Method Objective  
This type of design is used when the goal is shifted from product screening to 
product optimisation.  Response Surface Method (RSM) designs contain trails in 
which one or more of the variables are set at the mid-point of the study range. 
This allows us to estimate interaction on direct effects, pair-wise interaction 
effects, curvilinear variable effects and quadratic effects, therefore giving us an 
idea of the local shape of the response surface that we are investigating. 
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RSM designs are used to: 
 Find improved or optimal process settings; 
 Solve process problems and identify weak points; and 
 Make a product or process relatively insensitive to external and 
uncontrollable influences. 
 
To satisfy the objective of our studies, a RSM was most appropriate, due to the 
allowance for curvature. 
 
3.1.2 Response Surface Method Designs                           
Response surface models may involve just main effects and interactions, or in 
order to account for curvature, may have quadratic and cubic terms.  
 
3.1.2.1 Advantages of the Response Surface Design 
 Often, fewer simulation loops are required than a Monte Carlo Simulation 
method; 
 Low probability levels can be evaluated; 
 The goodness-of-fit parameters provide an approximation function as to 
how accurate the approximation function describes the true response 
parameter values. The goodness-of-fit can also provide a warning of when 
the approximation function is insufficient; and 
 The individual simulation loops are inherently independent, hence making 
this design ideal for parallel processing. 
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3.1.2.2 Disadvantages of the Response Surface Design 
 The total number of required simulation loops is dependant on the number 
of random input variables. This implies that if there is a large number of 
random input variables, then a probabilistic analysis would be impractical; 
and 
 These methods are not suitable for cases where a random output 
parameter is a non-smooth function of the random input variables. 
 
3.1.2.3 Response Surface Design Functions 
RSM designs can have a linear, quadratic or cubic function. If the response 
behaves in a linear manner (Figure 3.1a), the factors need only to be taken on 
two-levels. A two-level design, even with centre points can only detect pure 
quadratic effects, but cannot estimate them. If a response behaves as in Figure 
3.1b, then to quantify the pattern, a minimum number of three levels are utilised. 
A cubic function (Figure 3.1c) may be characterised by making use of a minimum 
of four levels of each factor. In general quadratic models are usually sufficient for 
industrial applications.       
 
 
 
 
 
 
(a)     (b)     (c) 
Figure 3.1 RSM functions: (a) Linear function, (b) Quadratic function  and (c) 
Cubic function 
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3.1.3 Quadratic Designs 
Classical quadratic designs were introduced during the 1950’s. These designs 
can be classified according to two broad categories: Central Composite designs 
and Box-Behnken designs. 
 
3.1.4 Central Composite Designs 
The Central Composite designs (CCD) contain an imbedded factorial or fractional 
factorial design with centre points, in addition to axial points, which allow for 
curvature, cube points are also present. Axial points are created by a screening 
analysis. Cube points are determined from a Full Factorial Design, whereas 
centre points are created by a nominal design. If the distance from the centre of 
the design space to a factorial point is ±1 unit for each factor, the distance from 
the centre of the design space to an axial point is ±α (IαI >1). The precise value 
of α depends on certain properties desired for the design and on the number of 
factors involved.  
 
The CCD is utilised to determine the coefficients of a second-order response 
surface model and is one of the most popular of the RSM designs due to the 
following three properties: 
 A CCD can be run sequentially. It can be partitioned into two subsets of 
points. The first subset estimates linear and two-factor interaction effects 
while the second subset estimates curvature effects. 
 CCDs are efficient, proving much information on experiment variable 
effects and overall experimental error in a minimum number of required 
runs. 
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 CCDs are very flexible. There are several varieties of CCDs that enables 
their use under different experimental regions of interest and operability. 
 
Three main varieties of CCDs are available: circumscribed central composite 
design (CCC), inscribed central composite design (CCI) and face-centred central 
composite design (CCF). 
 
3.1.4.1.1 Circumscribed Central Composite Design 
CCC designs provide high quality predictions over the entire design space. 
However factor settings outside the range of the factors in the factorial part are 
required. The axial points establish new extremes for the low and high factor 
settings (Figure 3.2).  
Cube Points 
-1 +1 
Axial Points
+1 
-1 
 
Figure 3.2 Arrangement of variable limits and axial points of the CCC 
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3.1.4.1.2 Inscribed Central Composite Design  
In contrast to CCC designs, CCI designs use only points within the factor ranges 
originally specified, hence the CCI explores the smallest space. This design is 
used when the limits specified for factor settings are truly limits. As a result the 
CCI design uses the factor settings as axial points (Figure 3.3), the fractional 
factorial design is created within those limits. Although this design also requires 5 
levels for each factor, it does not provide the same accuracy as the CCC.   
+1 
-1 
Cube Points 
-1 +1 
Axial Points
 
Figure 3.3 Arrangement of variable limits and axial points of the CCI  
 
3.1.4.1.3 Face Centred Central Composite Design 
The CCF design provides a relatively high quality of predictions over the entire 
design space. A distinct advantage that CCF designs have over CCC model, is 
that it does not require points to be set outside of the original factor range. 
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Making use of 3 levels of each factor, the axial points are at the centre of each 
face of the factorial space, so α =±1 as seen in Figure 3.4. 
 
Cube Points 
-1 +1 
Axial Points
-1 
 +1 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Arrangement of variable limits and axial points of the CCF 
 
3.1.4.2 Box-Behnken Designs 
The Box-Behnken design is a quadratic design that does not contain an 
embedded factorial or fractional factorial design. This design requires 3 levels of 
each factor. Like the CCI, the Box-Behnken design contains regions of poor 
prediction 
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 Figure 3.5 A Box-Behnken Design for three factors 
 
Of the various quadratic designs described above, a CCF was used in this study. 
A number of responses were identified which would provide valuable information 
necessary for the optimisation of the wafer.  
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Chapter 4      Preformulation Studies 
 
4.1 Introduction 
For the formulation of a rapidly disintegrating wafer, a polymer with low gelation 
characteristics is desired. The gelation potential of polymers is highly dependent 
on it’s solubility. General rules that govern the solubility of polymers (Rosen, 
1971) are as follows: 
 Like dissolves like; that is, polar solvents will tend to dissolve polar 
polymers and nonpolar solvents will tend to dissolve nonpolar polymers; 
 In a given solvent at a particular temperature, the solubility of a polymer 
decreases with an increase in molecular weight; and 
 The rate of polymer solubility 
- Increases with short branches, which loosen up the main-chain 
structure, allowing the solvent molecules to penetrate more easily; 
- Decreases with longer branches, because the entanglement of 
these branches makes it harder for the individual molecules to 
separate, and 
- Decreases with increasing molecular weight. 
 
Other factors that may affect the gelation of polymers include polymer 
concentration and for certain polymers, degree of acetylation (Montembault et al., 
2005). 
 
We predicted that the polymer within the system would play a pivotal role in 
output factors such as solubility, disintegration, mechanical strength and 
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hardness. Hence, the aim of the series of experiments outlined in this chapter 
was to select the most suitable polymer to provide rapid disintegration of the 
system and identify the lower and upper limits for the other variables used to 
generate the CCF.  
 
4.2 Materials and Methods 
Polymers utilised in the study include: sodium alginate (E401,Kelco Int. Ltd, 
London, UK), hydroxypropylmethyl cellulose (HPMC) (Methocel K4m Prem CR, 
The DOW Chem. Corp., Midland, Michigan, USA), hydroxypropyl cellulose (HPC) 
(Klucel, EF Pharm, Hercules Inc., Wilmington, North Carolina, USA), 
hydroxyethyl cellulose (HEC) (Natrosol, 250 G-Pharm, Hercules Inc., Wilmington, 
North Carolina, USA), pectin (Pectin Classic CM701, Herbstreith and Fox KG, 
Neuenburg, Germany), polyethylene oxide (PEO) (MW 7,000,000, Union Carbide 
Corp., Danburg, Connecticut, USA), polyvinyl alcohol (PVA) (MW 124,000 - 
186,000, Alrich, Milwaukee, Wisconsin, USA). Additionally lactose (Merck Lab 
Supplies Pty. Ltd., Midrand, Gauteng, South Africa) and. polystyrene cylindrical 
moulds of total volume 60.31mm³ (diameter 16mm and depth of 2.4mm) were 
utilised. 
 
Material used in the preparation of simulated saliva were: Potassium Phosphate 
Monobasic (KH2PO4) (Protea Lab Services Pty. Ltd., Gauteng, South Africa), 
Disodium Hydrogen Phosphate (Na2HPO4) (Saarchem Pty. Ltd., Krugersdorp, 
South Africa), Sodium Chloride (NaCl) (Labchem, Edenvale, South Africa).  
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4.2.1 Preparation of wafers 
Polymers suitable for oramucosal preparations were identified based on 
information provided in literature (Guo, 1994; Shojaei, 1998a; Miyazaki et al., 
2000; Yong et al., 2001; Ameye et al., 2002; Martin et al., 2002; Nafee et al., 
2003).  
 
A polymer (Table 4.1) (1%w/v) and lactose as a bulking agent (6%w/v) was 
added to deionised water and mixed for 45 minutes. 1.5mL of the various 
polymer solutions were pipetted into the cylindrical cavities pre-oiled with mineral 
oil. The formulation was subjected to a freeze-phase in a freeze-dryer (Bench 
Top 2K, Virtis, New York, USA) at -60°C for 2 hours. The drying-phase was 
executed at a pressure of 25 mtorr for 24 hours. Wafers were stored in glass jars 
with 2g of desiccant sachets.  
 
4.2.2 Analysis of wafers 
4.2.2.1 Weight Uniformity 
Weight uniformity was used to assess the reproducibility of wafer production 
process. Individual wafers were weighed, and standard deviations calculated. All 
experimentation was conducted in triplicate. 
 
4.2.2.2 Gelation of Matrices 
The main objective of this study was to formulate a rapidly dissolving wafer 
system. Thus the matrix formation characteristics required assessment and 
formed the basis for the selection of a suitable polymer. Gelation of the dosage 
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form would delay the disintegration and ultimately the release of active 
substance.   
 
A novel method was developed in order to assess the matrix forming profiles of 
the wafers. Wafers were weighed before being placed in a petri dish (diameter 
85mm, depth 10mm) containing 20mL of simulated saliva (pH 7.1). The petri dish 
was agitated for a period of 30 seconds on a Vortex Genie2 (Scientific Industries 
Inc. Bohemia, New York, USA) on the slowest setting. The contents of the petri 
dish were sieved through a stainless steel mesh (pore size 1mm). The mass of 
the remaining residue was determined on a balance (AB104-s, Mettler Toledo, 
Greifensee, Switzerland) and used to calculate the rate of matrix formation.  
 
The simulated saliva solution comprised 2.38g Na2HPO4, 0.19g KH2PO4 and 8g 
NaCl in 1000mL of deionised water (Tan et al., 2001). 
 
4.2.3 Determination Limits for Formulation Variables 
The lower and upper limits were determined using a trial and error method. 
Wafers of varying polymer and diluent concentrations (up to 30%w/v of each) 
were made and inspected visually.  
 
4.2.4 Development of the Manufacturing Process 
To establish the suitability of a mould in terms of ease of the system removal, 
well plates, blister packs and disposable polystyrene trays were assessed.  
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To overcome problems of wafers sticking to the mould, various lubricant systems 
were considered. Magnesium Stearate, Span 60, Maize oil and mineral oil were 
evaluated for their anti-adhesive properties. 
 
It was also necessary to determine suitable timeframes for the lyophilisation 
process.  
 
4.3 Results and Discussion 
4.3.1  Weight Uniformity 
The reproducibility of the production process was demonstrated by the low 
standard deviations (SD) calculated from the mass for each of the various 
polymer systems. Table 4.1 Shows the results obtained from the various polymer 
wafer systems. 
 
Table 4.1 Mean weight of wafers manufactured (N=3) 
Polymer Mean (g) ± SD 
HPC 0.126 ± 0.0017 
HPMC 0.122 ± 0.0002 
Pectin 0.134 ± 0.0055 
PEO 0.119 ± 0.0045 
PVA 0.118 ± 0.0011 
Sodium alginate 0.109 ± 0.0007 
 
Although the standard deviation of the samples is low, slightly higher values were 
observed for polymers such as pectin and PEO. This may be attributed to the 
high viscosity of the initial solution, and therefore greater variability in the 
production process.  
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4.3.2  Gelation of Matrices 
Polymers such as sodium alginate, pectin and PEO tended to form a gel-like 
substance when hydrated and agitated rather than undergo disintegration. 
Sodium alginate produced the highest amount of residue, possibly due to its low 
water solubility. In sharp contrast, the highly hydrophilic polymers such as HPC 
were completely disintegrated within 30 seconds into small particles which were 
able to penetrate through the pores on the sieve. Figure 4.1 shows the mass of 
intact material after sieving of the various dissolved wafers tested. 
 
Based on the results obtained, HPC was identified as the most suitable polymer 
for the wafer system, because no residue was produced after 30 seconds of 
hydration and agitation in simulated saliva. This may be attributed to the fact that 
HPC is highly soluble in polar solvents and therefore undergoes disintegration 
rapidly without forming a gel residue, ensuring rapid matrix disintegration. 
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Figure 4.1 Mass of intact wafer after gelation studies using various polymers 
(N=3) 
 
4.3.3 Established Parameters of Formulation Variables 
4.3.3.1 Concentration of HPC  
Lower and upper limits were determined to be 1%w/v and 10%w/v respectively. 
The upper limit of 10%w/v was set because wafers of higher polymer 
concentrations were difficult to remove from the mould. Some wafers produced 
with polymer concentrations below 5%w/v collapsed. Less than 1%w/v of HPC 
was not sufficient to form the wafer matrix.  
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4.3.3.2 Concentration of Diluent 
The concentration of the diluent would affect both the solubility and textural 
properties of the matrices. Lower and upper limits were determined to be 1%w/v 
and 5%w/v respectively. Concentrations of lactose higher than 5%w/v caused the 
wafer to be powdery and extremely fragile.  
 
4.3.3.3 Type of Mould 
A major problem that was encountered was the removal of the wafers from the 
moulds without disrupting the delicate structure. Polystyrene trays proved to be 
the most successful, with minimal deformation of the final product as these 
moulds could be easily split down the middle to release the wafer.   
 
4.3.3.4 Type of Lubricant 
As mentioned above, removal of the wafers from the mould was problematic. 
Mineral oil produced the greatest ease of removal of the product as compared to 
the other lubricants analysed, imparting minimal hydrophobicity and having no 
effect on the taste of the final product as opposed to other substances such as 
maize oil. 
 
4.3.3.5 Freeze-Drying Parameters 
Although the wafers appeared to be dry after a period of 24 hours, ‘melting’ and 
discolouration of the matrices occurred on storage. This was attributed to 
moisture present within the products, indicating that the freeze drying process 
needed to be conducted for a longer period. In future processes, this was 
increased to 48 hours. 
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4.4 Concluding Remarks 
It was necessary to gain a firm understanding of the key factors involved in the 
successful production of a lyophilised wafer system. HPC was selected as the 
most appropriate polymer of the seven that were assessed. It was expected that 
the type of diluent used in the wafer matrix would affect the disintegration rate of 
the wafers. Mannitol which is more quickly soluble than lactose will be included in 
the experimental design to assess its influence of this inclusion on the 
disintegration rate. The diluents will either be used on their own or in a 1:1 
combination. 
 
To solve the problem of wafers collapsing, Seager (1998) recommended that 
glycine be used as a collapse protectant. Therefore, concentrations of up to 
0.6%w/v will be included in subsequent formulations. 
 
The selection of a suitable polymer, determination of future formulation 
parameters and creation of problem-free manufacturing techniques formed the 
basis of this part of the study.  
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 Chapter 5      Experimental Design Strategy to Formulate and 
Evaluate the Wafer Matrix 
 
5.1 Introduction 
Once a suitable polymer was selected, in order to conduct a scientifically sound 
and rational study, a factorial experimental design was used. It was necessary to 
identify and optimise factors that were influential on the properties of the wafers, 
as well as the manufacturing process.  
 
The series of experiments discussed in this chapter aims to identify the effects of 
formulation variables on the physicochemical and physicomechanical properties 
of the wafers using a CCF to provide a systematic approach to the 
experimentation.  
 
5.2 Materials and Methods 
Ingredients used in the production of the wafers were hydroxypropyl cellulose 
(HPC) (Klucel, EF Pharm, Hercules Inc., Wilmington, North Carolina, USA), 
lactose (Merck Lab Supplies Pty. Ltd., Midrand, Gauteng, South Africa), mannitol 
(Merck Lab Supplies Pty. Ltd., Midrand, Gauteng, South Africa) and glycine 
(Aminoacetic Acid, Hopkin and Williams Ltd., Essex, England, UK) as a collapse 
protectant. 
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 5.2.1 Statistical Approach to Wafer Formulation 
A Face Centered Central Composite design was developed with 5 factors and 4 
centre points (Table 5.1).The equation for the design was as follows: 
 
Response = b0 + b1*s + b2*t + b3*u + b4*v + b5*w + b6*s*s + b7*t*t + b8*u*u + 
b9*v*v + b10*w*w + b11*s*t + b12*s*u + b13*s*v + b14*s*w + b15*t*u + b16*t*v + 
b17*t*w + b18*u*v + b19*u*w + b20*v*w     
         (Equation 5.1) 
Where: 
s = Polymer Concentration; 
t = Diluent Type; 
u = Diluent Amount;  
v = Glycine Concentration; and 
w = Fill Volume.  
 
The responses that were measured are:  
 Disintegration profiles; 
 Rate of influx of simulated saliva into the matrix; 
 Friability; 
 Matrix yield value; 
 Matrix tolerance; 
 Matrix absorption energy; 
 Matrix resilience; and 
 Brinell Hardness Number (BHN). 
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Table 5.1 Randomised experimental runs generated from the CCF  
Formulation 
Number 
[Polymer] 
(%w/v) 
Diluent 
Type 
[Diluent] 
(%w/v) 
[Glycine] 
(%w/v) 
Fill Vol. 
(mL) 
1 10 1 5 0.6 2 
2 5.5 0.5 3 0.6 1.5 
3 1 1 1 0 1 
4 5.5 0.5 3 0.3 1.5 
5 5.5 0.5 1 0.3 1.5 
6 10 1 1 0.6 1 
7 5.5 0 3 0.3 1.5 
8 5.5 1 3 0.3 1.5 
9 10 0.5 3 0.3 1.5 
10 10 1 1 0 2 
11 5.5 0.5 3 0.3 2 
12 10 0 5 0.6 1 
13 1 0 5 0.6 2 
14 5.5 0.5 3 0 1.5 
15 1 0 1 0.6 1 
16 10 1 5 0 1 
17 10 0 5 0 2 
18 5.5 0.5 5 0.3 1.5 
19 1 1 1 0.6 2 
20 1 0 5 0 1 
21 10 0 1 0.6 2 
22 1 0 1 0 2 
23 10 0 1 0 1 
24 1 0.5 3 0.3 1.5 
25 5.5 0.5 3 0.3 1.5 
26 5.5 0.5 3 0.3 1 
27 1 1 5 0 2 
28 1 1 5 0.6 1 
29 5.5 0.5 3 0.3 1.5 
30 5.5 0.5 3 0.3 1.5 
*Parenthesis indicate concentration 
*Diluent type: 0=lactose, 1=mannitol, 0.5= 1:1 mixture of lactose and mannitol  
*Glycine = matrix consolidator to increase rigidity 
 
5.2.2 Preparation of Wafers According to the CCF 
The composition of the wafers was specified by the CCF (Table 5.1). Ingredients 
were dissolved in deionised water and left to stir for 30 minutes. The specified 
volume of the solution was pipetted into polystyrene moulds pre-oiled with 2 
drops of mineral oil. The formulation was subjected to a freeze-phase in a freeze-
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 dryer at -60°C for 2 hours. The drying-phase was executed at a pressure of 25 
mtorr for 48 hours. Wafers were stored in glass jars with 2g of desiccant sachets. 
 
5.2.3 Evaluation of CCF Responses 
5.2.3.1 ANOVA Test 
An Analysis of Variance (ANOVA) was conducted on the input variables of the 
wafers to determine which input variables had a significant effect on the recorded 
output properties of the wafers. The ANOVA was carried out using Essential 
Regression and Experimental Design V2.207 (Yeaton, Stepper and Werner, 
1998). Only the linear terms were used to regress the data, since we were only 
interested in the effect that each input variable had on the measured output 
variables at a 95% confidence interval. 
 
5.2.3.2 Disintegration Profiles 
The definition of a fast melting (or disintegrating) tablet appeared in a compendial 
publication for the first time in 1998. However, neither the US Pharmacopeia nor 
the European Pharmacopeia have defined a specific disintegration test (Dobetti, 
2001). As a result, a novel method was developed to assess and compare the 
disintegration profiles of the 30 samples manufactured according to the CCF.  
 
Wafers were weighed before being placed in a petri dish containing 20mL of 
simulated saliva (as described in Chapter 4, section 4.3.2.2). The dish was 
allowed to slowly agitate on a vortex mixer for a period of 20 seconds. The 
contents of the dish were sieved through a stainless steel mesh (pore size 1mm). 
Particles that were able to pass through the pores of the sieve were considered 
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 to be sufficiently disintegrated, while those captured by the sieve were termed the 
‘residue’. The residue represents the portion of the wafer that was not sufficiently 
disintegrated. The residue was measured in both the hydrated and dry state. For 
wafers that were eroded very rapidly, the agitation time was reduced to 10 
seconds. Tests were conducted in triplicate. Based on the measurements 
documented, the following information was calculated, providing a 
comprehensive disintegration profile for each wafer formulation:  
 
Normalised Percentage Matrix Disintegrated per second (%/s)  
Time
tatWaferUnhydratedofMass
WafertegratedDiofMass 100sin
0
×⎟⎟⎠
⎞
⎜⎜⎝
⎛
    (Equation 5.2) 
 
To account for the different times used for certain formulations, as well as the 
difference in wafer size caused as a result of the various fill volumes (1mL, 1.5mL 
and 2mL) used in the CCF, the Percentage Matrix Disintegration was calculated 
per second. This process expresses the results as a fraction such that 
differences in formulation are taken into account, and are comparable on a 
normalised level. 
 
Influx Rate of Simulated Saliva within Wafer (%/s) 
Time
WaferHydratedofMasssidual
WafersidualDryofMassWaferHydratedofMasssidual 100
Re
ReRe ×⎟⎟⎠
⎞
⎜⎜⎝
⎛ −
 
         (Equation 5.3) 
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 Similar to the disintegration profiles, the influx of simulated saliva is calculated as 
a rate, allowing the various formulations to be compared on the unit percentage 
per second.  
 
5.2.3.3 Friability 
Rapidly disintegrating systems prepared by the process of lyophilisation are 
known for having the characteristic disadvantage of poor physical resistance 
(Dobetti, 2001). Problems anticipated as a result of this include: breakage of 
tablet edges during handling and the inability of the tablet to be ejected and 
removed from a conventional blister alveolus. These features need to be taken 
into consideration when determining the packaging of the product.  
 
Friabilty was measured using a Roche friabilator (Hoffman la Roche, Basel, 
Switzerland). The wafers (N=3) were accurately weighed before being placed into 
the friabilator. A rotation time of 4 minutes at 25 rpm was used. Tablets were 
removed and loose particles brushed off the surface. Wafers were re-weighed 
and the percentage weight loss was calculated.  
 
5.2.3.4 Textural Analysis 
This study focuses on the characterisation of matrix resilience, energy of 
absorption, matrix yield value and matrix tolerance, using the TA.XTplus Texture 
Analyser (Stable Micro Systems, Surrey, UK) fitted with a 5kg load cell.  
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 5.2.3.4.1 Energy of Absorption 
The energy of absorption is an indirect indication of the porosity of the wafers. A 
highly porous wafer will exhibit a greater value for the energy of absorption 
because energy is accommodated within the voids in the matrix. The energy of 
absorption is calculated by determining the area under the curve (AUC) of a 
profile illustrating force (N) and distance (m) (Figure 5.1). Note that for the AUC, 
the units of Newton metre (Nm) are equivalent to Joules. 
 
 
Figure 5.1 Calculation of energy of absorption (i.e. AUC) 
 
5.2.3.4.2 Matrix Yield Value 
This test is indicative of a surface phenomenon, providing information about the 
superficial, surface structure of the wafer. The matrix yield value is determined by 
creating a gradient between anchors 1 and 2 (Figure 5.2). Anchor 2 represents 
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 the first point of major inflection on the force-distance profile. This is indicative of 
primary fracture of the wafer matrix which results in a reduction of force.  
 
 
Figure 5.2 Determination of matrix yield value 
 
5.2.3.4.3 Matrix Tolerance 
On further application of force, the residual intact matrix undergoes complete 
fracture (Figure 5.3). The matrix tolerance value is indicative of the overall 
strength of the wafer. The second anchor indicates the point of maximum force. 
The gradient between anchors 1 and 2 in Figure 5.3 is the matrix tolerance value. 
This indicates the point at which total collapse of the matrix occurs. 
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Figure 5.3 Determination of matrix tolerance 
 
5.2.3.4.4 Matrix Resilience 
Matrix resilience profiles provide us with an understanding of the deformation 
characteristics and the ability of the wafer to withstand pressure. The calculation 
of matrix resilience is provided by the ratio of the AUC between anchors 2 and 3 
and between anchors 1 and 2 as shown in Figure 5.4.  
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Figure 5.4 Force-time profile for the calculation of matrix resilience. 
 
5.2.3.4.5 BHN 
The BHN is an indication of the force required to indent the surface of the wafer, 
and is thus a measure of the hardness of the surface of the wafer.  BHN is 
calculated using the following equation: 
( )22
2
dDDD
F
BHN −−
Π=       (Equation 5.4) 
Where: 
D = Diameter of ball probe = 3.175mm 
d = Depth of indentation = 0.25mm 
F = Force, determined from Figure 5.5. 
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Figure 5.5 Force-distance profile for the computation of the BHN 
 
5.3 Results and Discussion 
The complete results for the ANOVA are shown in Table 5.2. The measured 
responses of the CCF are shown in Table 5.3 and Table 5.4.  
Table 5.2 Results of ANOVA conducted on wafer systems 
Output 
Variable  
Term Coefficient t - Statistic Significance 
(p value) 
Constant 4.899 1.255 0.223 
[HPC] %w/v -0.770 -3.369 0.00277 
Diluent Type 1.870 1.817 0.08287 
[Diluent] %w/v 1.100 2.138 0.04385 
[Glycine] 
%w/v 
1.972 0.575 0.571 
Disintegration 
Rate 
(%/s) 
Fill Vol. (mL) -0.706 -0.343 0.735 
 
Constant 8.729 2.346 0.02838 
[HPC] %w/v -0.603 -2.767 0.01124 
Diluent Type 2.025 2.064 0.05098 
[Diluent] %w/v 0.738 1.505 0.147 
[Glycine] 
%w/v 
0.762 0.233 0.818 
Influx of 
Simulated 
Saliva 
(%/s) 
Fill Vol. (mL) -1.783 -0.909 0.373 
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 Table 5.2 continued  
Output 
Variable  
Term Coefficient t - Statistic Significance 
(p value) 
Friability Constant 3.034 0.465 0.647 
(% loss) [HPC] %w/v -0.932 -2.435 0.02344 
 Diluent Type 1.637 0.951 0.352 
 [Diluent] %w/v 1.967 2.285 0.03233 
 [Glycine] 
%w/v 
-8.109 -1.413 0.172 
 Fill Vol. (mL) 1.176 0.341 
 
0.736 
Constant -0.02816 -2.685 0.01354 
[HPC] %w/v 0.00374 6.088 3.975e-06 
Diluent Type 0.00117 0.422 0.677 
[Diluent] %w/v 0.00144 1.045 0.307 
[Glycine] 
%w/v 
-0.00444 -0.482 0.634 
Energy 
Absorbed 
(J) 
Fill Vol. (mL) 0.02189 3.958 0.000668 
 
Constant 5.430 2.958 0.00728 
[HPC] %w/v -0.211 -1.962 0.06255 
Diluent Type 0.609 1.259 0.221 
[Diluent] %w/v -0.411 -1.697 0.104 
[Glycine] 
%w/v 
0.261 0.162 0.873 
Matrix Yield 
Value 
(N/mm) 
Fill Vol. (mL) -1.070 
 
-1.105 0.281 
Constant 58.68 3.950 0.000682 
[HPC] %w/v -2.686 -3.086 0.00540 
Diluent Type 2.799 0.715 0.482 
[Diluent] %w/v -4.570 -2.334 0.02915 
[Glycine] 
%w/v 
1.185 0.09074 0.929 
Matrix 
Tolerance 
(N/mm) 
Fill Vol. (mL) 
 
-11.37 
 
-1.451 0.161 
Matrix 
Resilience 
Constant 22.59 2.088 0.04863 
(%) [HPC] %w/v -0.603 -0.951 0.352 
 Diluent Type -3.832 -1.343 0.193 
 [Diluent] %w/v 1.640 1.150 0.262 
 [Glycine] 
%w/v 
-12.28 -1.291 0.210 
 Fill Vol. (mL) -9.019 -1.581 0.128 
 
BHN Constant -0.122 -0.09834 0.923 
(N/mm2) [HPC] %w/v 0.454 6.237 2.816e-06 
 Diluent Type -0.114 -0.348 0.731 
 [Diluent] %w/v 0.268 1.637 0.116 
 [Glycine] 
%w/v 
2.513 2.301 0.03124 
 Fill Vol. (mL) -0.937 -1.430 0.167 
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Table 5.3 Data generated from disintegration and friability analysis 
Formulation 
Number 
Rate of Matrix 
Disintegration 
(%/sec) 
Rate of 
Simulated Saliva 
Influx (%/sec) 
Friability (% 
Loss) 
 
1 1.60 3.32 0.46 
2 1.94 3.39 1.28 
3 2.44 8.30 0.67 
4 2.77 4.14 0.77 
5 2.35 3.97 0.08 
6 0.55 3.37 1.14 
7 1.44 3.51 0.69 
8 4.02 4.04 0.60 
9 0.64 3.04 0.05 
10 0.89 2.98 0.42 
11 0.06 3.54 0.19 
12 0.01 3.05 0.34 
13 5.73 3.38 2.63 
14 1.39 3.59 0.51 
15 5.77 7.62 1.72 
16 2.32 3.92 0.31 
17 1.13 3.38 0.50 
18 2.34 3.46 0.44 
19 3.40 3.80 0.53 
20 4.67 4.22 19.73 
21 1.82 3.53 0.38 
22 3.45 4.37 0.96 
23 0.70 3.40 0.33 
24 3.42 3.95 0.55 
25 1.02 3.55 4.11 
26 1.16 3.62 0.07 
27 18.18 18.18 40.72 
28 25.00 25.00 11.90 
29 0.84 3.59 0.28 
30 0.62 3.46 0.50 
R2 0.969 0.955 0.942 
*R2 – for validation of model according to predicted data 
 
The data in Table 5.3 is shown to two decimal places, however four decimal 
places were employed during calculations to ensure precision and accuracy. 
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 Table 5.4 Textural profiling analysis conducted on wafers 
Formulation 
Number 
Matrix Yield 
Value 
(N/mm) 
Matrix 
Tolerance 
(N/mm) 
Matrix 
Absorption 
Energy (J) 
Matrix 
Resilience 
(%) 
BHN  
(N/mm2) 
1 1.25 4.47 0.06 4.66 6.19 
2 1.10 5.69 0.03 4.36 2.35 
3 10.03 80.22 0.01 3.97 1.50 
4 2.09 4.98 0.03 3.71 1.90 
5 0.14 5.44 0.02 4.27 1.92 
6 1.19 6.14 0.03 6.09 6.67 
7 0.77 4.64 0.04 3.00 6.11 
8 0.21 4.70 0.02 5.24 2.88 
9 0.88 5.79 0.04 5.25 4.53 
10 0.98 4.02 0.08 5.49 2.41 
11 1.12 4.47 0.06 4.40 0.46 
12 1.73 7.65 0.04 6.90 8.14 
13 0.09 4.40 0.02 2.65 1.01 
14 0.27 5.14 0.02 5.38 0.52 
15 3.12 54.64 0.01 7.13 0.05 
16 0.57 7.10 0.03 8.64 3.59 
17 0.70 3.84 0.07 3.10 5.20 
18 0.74 4.58 0.03 3.13 1.69 
19 3.94 41.12 0.01 3.18 0.08 
20 0.17 8.61 0.01 7.18 0.65 
21 1.36 7.17 0.04 6.50 3.58 
22 0.20 8.67 0.01 4.78 0.20 
23 0.75 7.65 0.02 5.71 1.81 
24 7.24 63.84 0.01 2.39 0.44 
25 0.79 4.93 0.03 3.15 1.76 
26 0.40 8.10 0.02 4.59 3.77 
27 0.20 4.77 0.02 2.10 0.01 
28 1.50 5.11 0.01 3.20 1.39 
29 0.32 5.27 0.02 3.75 0.01 
30 0.86 4.75 0.03 3.14 2.71 
R2 0.855 0.916 0.923 0.956 0.897 
*R2 – for validation of model according to predicted data 
 
The data presented in Table 5.4 is to two decimal places, however four decimal 
places were employed during calculations to ensure precision and accuracy. 
 
5.3.1 ANOVA 
Table 5.2 lists the results of the ANOVA on the variables tested together with the 
regression coefficients of the linear terms. 
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 The ANOVA for a total of 28 points for each output variable reveals that for 
friability, disintegration rate and matrix tolerance, the concentration of HPC and 
diluent are the only formulation factors that had any significant effect on them (p< 
0.05). The type of diluent, concentration of glycine and fill volume had no 
significant effect on the friability, disintegration rate and matrix tolerance of the 
wafers tested. The concentration of HPC also had a significant effect on the influx 
of simulated saliva rate, BHN and energy absorbed. The only output variables 
that the concentration of HPC had no significant effect on were the matrix 
resilience and yield value. In fact no input variables had any significant effect on 
the matrix yield value and resilience of the wafers. Therefore, the matrix 
resilience and yield value were not considered to be reliable measures that would 
discern between the effects of different input variables on optimising the wafer 
formulation. 
 
Glycine concentration did however have a significant effect on the BHN, probably 
due to the fact that as it increases in concentration, it decreases the plasticity of 
the wafers. The only factor that was influenced by the type of diluent used was 
the rate of saliva influx. The different diluents may contribute to varying the 
solubility of the wafers. Besides the matrix absorption energy, the fill volume did 
not influence any other variable measured in this study.  
 
5.3.2 Disintegration Profiles 
Based on the results (Table 5.3), it could be seen that the rate of disintegration of 
the wafers was primarily dependent on the concentration of HPC, and 
secondarily on the concentration of the diluents (Figure 5.6). It was generally 
noted that higher polymer concentrations were associated with lower rates of 
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 disintegration. Due to the highly soluble nature of the diluents, an increase in the 
amount accounted for higher matrix solubility and thus faster rates of 
disintegration.  
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Figure 5.6 Surface plot illustrating the effect of diluent and HPC concentration on 
the rate of matrix disintegration 
 
Formulations containing low polymer concentrations, accompanied by high 
concentrations of diluent, underwent significantly rapid disintegration. It was also 
noted that the presence of mannitol in the formulations promoted more rapid 
disintegration than those containing lactose. This phenomenon can be explained 
by comparing the solubility of the two sugars. Although solubility of mannitol and 
lactose are similar (1g in 5.5 and 5mL of cold water respectively, Windholz et al., 
1976), it was noted that lactose dissolve at a slower rate than mannitol. The more 
rapid disintegration rates of formulations containing mannitol can be directly 
attributed to its better solubility than lactose.  
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Figure 5.7 Relationship between the influx of simulated saliva and disintegration 
of the wafers (N=3) 
 
Another factor that affected the rate of disintegration was the influx of simulated 
saliva. It was observed that as saliva was imbibed into the wafer, disintegration 
was promoted (Figure 5.7). The ability of saliva to be imbibed into the wafer was 
attributed to the porous structure created, as a result of the freeze drying 
process. The results of the ANOVA analysis (Table 5.2) indicated that the 
formulation variable to have the most significant effect on the influx of saliva was 
the concentration of HPC. It was therefore deduced that an increase in the 
concentration of HPC allows for the creation of pores within the wafer during the 
lyophilisation process. The concentration of diluent also plays an important role in 
the rate of saliva influx. 
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 5.3.2.1 Predicted Disintegration Response 
The close correlation between the experimental and predicted responses for the 
rate of matrix disintegration can be clearly seen in the plot below (Figure 5.8). 
The correlation coefficient (R2) obtained is 0.97. The standard deviation for this 
comparison is 1.66.  
 
The equation that describes the response (Figure 5.8) is as follows: 
y   =  1.2013 – 3.4672*s + 1.8698*t + 2.2004*u + 0.5916*v – 0.3528*w 
+0.8852*s*s + 1.5822*t*t + 1.1977*u*u + 0.5152*v*v - 0.5348 w*w – 1.7330*s*t – 
2.3389*s*u – 0.7629*s*v + 0.5606*s*w + 2.5017*t*u +0.2095*t*v – 0.4505*t*w + 
0.1239*u*v -0.3421*u*w – 2.0179*v*w       
         (Equation 5.5) 
Where s, t, u, v and w are as described in Equation 5.1. 
 
Similarly, the high accuracy of the CCF predictions can be seen for the rate of 
influx of simulated saliva (Figure 5.9). The standard deviation and R2 were 1.79 
and 0.96 respectively.  
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R2 = 0.97
Figure 5.8 Comparison of the experimental and predicted responses for the 
matrix disintegration rate 
 
The equation describing the response (Figure 5.9) is as follows.  
y   =  3.22095 – 2.71411*s + 2.02478*t + 1.47594*u + 0.22856*v – 0.89128*w + 
0.50857*s*s + 0.78557*t*t + 0.72607*u*u + 0.50057*v*v - 0.59207 w*w – 
2.21656*s*t – 1.64331*s*u – 0.32056*s*v + 0.92981*s*w + 2.30381*t*u - 
0.00669*t*v – 0.54206*t*w + 0.36031*u*v - 0.00369*u*w – 2.13006*v*w 
         (Equation 5.6) 
Where s, t, u, v and w are as described in Equation 5.1 
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R2 = 0.96
Figure 5.9 Comparison of the experimental and predicted responses for the rate 
of influx of simulated saliva 
 
5.3.3 Friability 
Preliminary investigations have shown that lactose may possess a superior 
binding ability to mannitol during wafer preparation. From the results in Table 5.2 
it was observed that the friability of the wafers was dependant on the 
concentration of polymer (p= 0.063). Low friability was seen in wafers containing 
high concentrations of HPC. The most friable wafers were those containing low 
concentrations of polymer accompanied by high concentrations of diluent, as 
seen in the surface plot (Figure 5.10). From this it may be concluded that the 
polymer served as a binding agent, thus imparting robust qualities to the wafer. 
When determining optimal concentrations for the diluent, it should be kept in mind 
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 that although high diluent concentrations promoted rapid dissolution, this also led 
to an increase in friability.  
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Figure 5.10 Surface plot of friability demonstrating the effects of diluent and HPC 
concentration 
 
5.3.3.1 Predicted Friability Response 
The precision of the design prediction for the friability of the wafers is highlighted 
by the R2 value of 0.94.  
 
The equation below describes the response (Figure 5.11) 
y   =  0.10301 – 4.1935*s + 1.6374*t + 3.9343*u – 2.4327*v + 0.5879*w + 
0.8511*s*s + 1.1986*t*t + 0.8095*u*u + 1.4470*v*v + 0.6785 w*w – 1.7506*s*t – 
4.4849*s*u + 2.8785*s*v – 0.6974*s*w + 1.9261*t*u – 0.7268*t*v + 2.8599*t*w – 
2.9570*u*v + 0.8504*u*w – 2.0417*v*w     
         (Equation 5.7) 
Where s, t, u, v and w are as described in Equation 5.1. 
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R2 = 0.94
Figure 5.11 Comparison of the experimental and predicted responses for friability 
 
5.3.4 Values Generated from Textural Profiling  
Table 5.4 depicts the observed values of the textural responses for the 30 wafer 
formulations, as per CCF. It is apparent that all wafers possessed significantly 
different textural properties, based on the wide intra-response variation.  
 
No input variables had a significant effect on the matrix yield value and matrix 
resilience (Table 5.2). The concentration of polymer and diluent were shown to 
cause a decrease in the matrix tolerance (Figure 5.12). It was postulated that an 
increase in the HPC concentration resulted in an increase in the porosity of the 
wafer. Resulting from an increase in porosity, a corresponding increase in 
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 plasticity was also seen. The matrix was therefore unable to resist the force 
applied by the probe and was fractured by lower forces. On the other hand, an 
increase in the amount of diluent present in the system created a consolidated 
wafer resulting in greater compactness of the matrix. This compact matrix was 
brittle in nature and fractured by lower forces. 
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Figure 5.12 Surface plot illustrating the reduction in matrix tolerance as a result of 
increasing diluent and HPC concentration 
 
The concentration of HPC also had a significant impact on the BHN. The HPC 
imparts rigidity and thus increases the surface hardness of the wafers. An 
increase in the concentration of glycine also resulted in an increase in the BHN 
(Figure 5.13). These results show that glycine was successful in acting as a 
consolidator. 
 
The variables that significantly affected the matrix absorption energy were the fill 
volume and the HPC concentration (Figure 5.14). As the fill volume and hence 
the size of the wafer increased, the capacity to absorb energy increased as a 
direct result of greater area available for the propagation and dissipation of 
energy. As mentioned earlier, an increase in the concentration of HPC enabled 
the wafer with a greater ability to form pores. The spaces within the wafer allowed 
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 for the entrapment of energy and therefore a greater ability for energy absorption 
with increasing concentrations of polymer. 
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Figure 5.13 Surface plot illustrating the effect of diluent and HPC concentration 
on the BHN  
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Figure 5.14 Surface plot illustrating the effect of fill volume and HPC 
concentration on the matrix absorption energy 
 
5.3.4.1 Prediction of Textural Parameters by the CCF 
A close relationship was observed between the experimental and predicted 
values (Figure 5.15) depicts the relationship between the observed and predicted 
values for each response. 
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Figure 5.15 Profiles depicting the relationship between the experimental and 
predicted values for each dependent variable: (a) Matrix yield value; (b) Matrix 
tolerance; (c) Matrix absorption energy; (d) BHN and (e) Matrix resilience 
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 A close correlation can be seen between these profiles. The similarity of the 
experimental and predicted data is highlighted by an average correlation 
coefficient of 0.91 for the above responses.  
 
5.3.5 Porosity of the Wafers 
Poor resilience may be attributed to large pores and voids within the spongy 
matrix. The irregular peaks seen between the anchors 2 and 3 in Figure 5.16 are 
indicative of the porosity of the wafers. The bounce on the curve was caused by 
the air pockets within the matrix. These were larger at the surface, as 
compression continued air was forced out of the spongy matrix.  
 
 
Figure 5.16 Typical force-time profile showing matrix resilience 
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 5.3.6 Relationships between Textural Analysis Responses 
5.3.6.1 Matrix Tolerance vs. Energy of Absorption 
It was observed that an increase in matrix tolerance was accompanied by a 
decrease in the work performed during probe penetration (Figure 5.17). This 
indicated that as the matrix became more resistant to fracture, the energy 
generated by stress was not dissipated. The observed reduction in energy may 
be a result of its absorption within the wafer matrix. This absorption would also be 
facilitated by the large number of voids within the wafer. 
 
Formulation Number
0 5 10 15 20 25 30
M
at
rix
 T
ol
er
en
ce
 (N
/m
m
)
0
20
40
60
80
100
En
er
gy
 o
f A
bs
or
pt
io
n 
(N
m
)
0.00
0.02
0.04
0.06
0.08
0.10
Matrix Tolerence 
Energy 
 
Figure 5.17 Inverse relationship between the wafer matrix tolerance and energy 
of absorption 
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 5.3.6.2 Brinell Hardness vs. Energy of Absorption 
The overall pattern of the profile (Figure 5.18) indicates that there was a directly 
proportional relationship between the BHN and the matrix absorptive energy. The 
absorptive energy is an indication of the wafer matrix ability to withstand 
distension prior to relaxation. The indentation hardness (depicted by the BHN) is 
a high pressure point measurement (force/unit area). Contact of the textural 
probe with the matrix resulted in the dissipation of high energy which was 
subsequently absorbed. The dissipation of energy appeared to be faster than the 
propagation and absorption, hence smaller energy values were apparent.   
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Figure 5.18 Comparison between Brinell Hardness Number and energy of 
absorption 
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 5.3.6.3 Matrix Yield vs. Matrix Tolerance 
A direct relationship between the matrix yield value and tolerance is illustrated in 
Figure 5.19. Significantly low yield values are due to the initial high energy levels 
within the wafer, therefore a low force was required to split the wafer. Once the 
wafer is fissured, the energy is dissipated throughout the matrix which eventually 
reaches a threshold called matrix tolerance, when the structure collapses.  
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Figure 5.19 Correlation between matrix yield value and tolerance 
 
5.4 Concluding Remarks 
During the optimisation of the wafer system, matrix disintegration and friability are 
of utmost importance. The experiments prove that these responses are 
manipulated by varying formulation excipients such as HPC and diluent 
concentrations. 
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 The elucidation of various textural parameters to ascertain the 
physicomechanical behaviour of the wafers proved to be sensitive based on 
subtle changes in the formulation as per statistical design. This can be beneficial 
in terms of being able to optimise these parameters to meet criteria acceptable to 
the pharmaceutical industry for manufacturing purposes. 
 
Among the various parameters evaluated, the matrix resilience is key to 
understanding the deformation characteristics. This property will ultimately 
determine an appropriate packaging method. 
 
The use of statistical design was successful in providing a structured approach to 
the formulation of the wafer system. The data generated through the 
measurement of responses was meaningful and allowed for the identification of 
the formulation factors which were influential in altering the response. This allows 
for further manipulation of these factors to gain an optimal wafer system. 
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Chapter 6      Assessment of Glass Transition Temperature 
 
6.1 Introduction 
Differential Scanning Calorimetry (DSC) is one method of assessing the glass 
transition temperature (Tg) of materials. Glass transition involves the transition 
from a “glassy” solid to a “rubbery” liquid-like state. This change occurs within a 
temperature range characteristic for each material. The mid-point temperature of 
such a change is taken as the Tg (Sobral et al., 2001). With respect to polymers, 
as the temperature of the material drops below the Tg, they behave in a brittle 
manner, and as the polymer temperature rises above the Tg, it becomes more 
rubber-like.  
 
It was reported by Simon and co-workers (2003) that the process of lyophilisation 
affects the Tg of the material. Glass transition temperature is depressed by 
freeze-drying from dilute solution and by precipitation from dilute solution 
(Bernazzani et al., 2002, Simon et al., 2003). It is hypothesized that the Tg is an 
important parameter for storage, stability and quality of dried or frozen products 
(Sobral et al., 2001). Freeze-dried products are less likely to collapse if stored 
below Tg (Craig et al., 1999). It was therefore necessary to gain a complete 
understanding of the behavior of our wafers during the freeze drying-process. 
 
In addition to the quantitative studies used as responses for the CCF, DSC was 
also carried out on the wafers. The qualitative nature of this experiment did not 
lend itself for inclusion into the CCF, however the effect of the lyophilisation 
process on wafer components was important to assess. The Tg of material also 
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provides an indication of stability, permitting information about storage conditions 
to be extrapolated. 
 
6.2 Materials and Method 
The 30 wafer formulations that were previously manufactured (Chapter 5, section 
5.3.2) according to the CCF were analysed. 
 
6.2.1 DSC 
DSC studies were conducted on the 30 wafer formulations as well as individual 
wafer components. A linear temperature gradient at a rate of 5˚C per minute was 
performed from 25˚C to 400˚C (Perkin Elmer Pyris-1). Samples of 2-3mg were 
placed within crimped aluminium pans and subjected to the test. 
 
6.3 Results and Discussion 
6.3.1 DSC 
Typical thermal curves of the pure components of the various wafer systems are 
shown in Figure 6.1. The Tg of HPC occurred at 75.28˚C. The large endothermic 
peak at the Tg may be due to vaporisation of low molecular mass components of 
the polymer (Hatakeyama and Quinn, 1999). Degradation of the polymer 
structure was observed at 336.81˚C and 364.53˚C. Mannitol exhibited a Tg at 
163.11˚C, while also undergoing degradation above 360˚C. The thermogram for 
lactose showed not only the Tg at 143.35˚C, but also an endothermic peak in the 
region of 210˚C indicative of the melting of the sugar. Peaks that were seen at 
236˚C and 296˚C may be the result of impurities present in the lactose, or 
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degradation products of the sugar. The experimental Tg of glycine was found at 
167.58˚C, and the highly endothermic peak at 262˚C is indicative of its 
degradation.  
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(d) Glycine 
Figure 6.1Differential Scanning Calorimetry profiles for: (a) HPC; (b) Mannitol; (c) 
Lactose; and (d) Glycine 
 
 
In general a reduction in the Tg of the HPC was observed for the 30 wafer 
formulations, with the transition temperature ranging from 59.99˚C to 73.43˚C. A 
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typical profile for the wafers is illustrated in Figure 6.2. Since freeze-dried 
products have extremely low moisture content, the depression in Tg cannot be 
attributed to the presence of a solvent. The lyophilisation process was shown to 
reduce the entanglement of polymeric chains. It was hypothesised that this may 
have led to a reduction in the Tg. However a study conducted by Simon and co-
workers (2003) indicated that the reduction in entanglement is not responsible for 
the change in the Tg.   
 
The reduction in the melting point (213˚C to 211˚C) of the wafer was anticipated 
and can be attributed to the decrease in water content after freeze drying (Sobral 
et al., 2001). The lower melting point may also be as a result of an interaction 
between the polymer and excipients. 
 
A decrease in the height of the enthalpy recovery peak for the freeze-dried wafer, 
as compared to individual excipients may possibly be attributed to the decrease  
in thermal conductivity, due to the porous nature of the material (Simon et al., 
2003). 
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Figure 6.2 Typical Differential Scanning Calorimetry profile of a wafer formulation 
(F2). 
 
6.4 Concluding Remarks 
Although a reduction in the Tg occurred after the freeze drying process, the Tg of 
the wafers is still above the temperature of storage and processing, and thus is 
not of concern regarding product stability. 
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Chapter 7      Statistical Optimisation of Wafer Matrices 
 
7.1 Introduction 
Fonner and co-workers (1970) were among the first researchers to introduce the 
application of mathematical optimisation into the field of pharmaceutics, using the 
Lagrangian method as a constrained optimisation technique. Among the different 
methods that are available for solving constrained optimisation problems, the 
most common are Lagrangian and Simplex methods. The evolution of computer 
science has enabled the incorporation of the optimisation algorithm into the 
experimental design software.  
 
A pure trial and error approach to optimisation would be extremely time 
consuming. Statistical software perform extensive analysis of the observed 
outputs and their rates of change as the inputs are varied, to guide the 
selection of new trial values. This study makes use of a generalised reduced 
gradient algorithm (GRG2) and Artificial Neural Networks (ANN). 
 
The GRG2 is an algorithm that solves nonlinear optimisation problems by 
implementing a variation of the generalised reduced gradient method. GRG2 
uses first partial derivatives of each function with respect to each variable. These 
are automatically computed by finite difference approximation. Once the initial 
data has been entered, the algorithm enters a two phase system for problem 
solving. Phase I objective function is the sum of the extent of constraint range 
violations including a fraction of the true objective. If a feasible solution is not 
found, this phase may terminate, indicating that the problem is not feasible. 
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Phase II begins with the feasible solution found in Phase I. A full optimisation 
cycle is run and a summary output is provided at the end of Phase II.  
 
Another method of optimisation is the use of ANN. The application of ANN in 
advanced formulation design and development is being increasingly employed 
(Ibric et al., 2003; Leanne et al., 2003; Subramanian et al., 2004). In this study, a 
General Feedforward (GFF) model was selected to predict the rate of matrix 
disintegration, friability and resilience values using the statistical matrix generated 
from the CCF. Essentially a GFF is a generalisation of a Multilayer Perceptron 
(MLP) such that network connections can jump over one or more hidden layers 
(Figure 7.1). In theory, a MLP can solve any problem that a GFF network can 
solve. In practice, however, GFF networks solve the problem much more 
efficiently (Nelson and Illingworth, 1992; Principe et al., 1999). Such a network 
containing the same number of processing elements, as a standard MLP requires 
less training, hence increasing the efficiency of neurocomputing.  
 
The objective of the experimentation undertaken in this Chapter was to optimise 
the properties of the wafer to generate an ‘ideal’ wafer formulation in terms of 
disintegration rate, friability and resilience.  
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Figure 7.1 Schematic representation of a Multilayer Perceptron 
 
7.2 Materials and Methods 
Ingredients used in the production of the wafers were hydroxypropyl cellulose 
(HPC) (Klucel, EF Pharm, Hercules Inc., Wilmington, North Carolina, USA), 
lactose (Merck Lab Supplies Pty. Ltd., Midrand, Gauteng, South Africa), mannitol 
(Merck Lab Supplies Pty. Ltd., Midrand, Gauteng, South Africa), glycine 
(Aminoacetic Acid, Hopkin and Williams Ltd., Essex, England, UK) and 
diphenhydramine hydrochloride (Sigma-Aldrich, Steinheim, Germany) as a model 
drug. 
 
All wafers described in this section were manufactured according to the method 
described in Chapter 5, section 5.3.2. The matrix disintegration rate, friability and 
matrix resilience studies were conducted as outlined in Chapter 5, section 5.3.3 
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7.2.1 GRG2 Optimisation 
Based on the fact that the CCF follows a quadratic model, it was most 
appropriate to employ a GRG2 algorithm, solver technology (Frontline system 
ms, USA) to obtain the ideal response values for the optimal matrix 
disintegration rate, matrix resilience and friability using constraints that 
regulate the three-dimensional configuration of the wafer matrices. 
The limitations placed on the independent input variables were as follows: 
 1≤ [HPC] ≤10 %w/v; 
 Type of Diluent 0-1, 0= lactose and 1=mannitol; 
 1≤ [Diluent] ≤5 %w/v; 
 0≤ [Glycine] ≤0.6 %w/v; and 
 1≤ Fill Volume ≤2 mL. 
 
Optimal responses for the desired training of data are depicted in Table 7.1. The 
rate of matrix disintegration was calculated such that the wafer would ideally 
disintegrate completely in 30 seconds (100%/30s = 3.33%/s). The parameters for 
friability were determined according to the USP 23 standard for conventional 
tablets. The matrix resilience was set to achieve the maximum feasible value.  
 
Table 7.1 Desired values for the responses to develop an optimised formulation 
Response Minimum Maximum Optimal 
Rate of Matrix 
Disintegration (%/s) 
 
1 
 
6 
 
3.33 
Friability (% loss) 0 0.8 0.1 
Matrix Resilience 
(%) 
95 100 Maximize 
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7.2.2 ANN Optimisation 
For the hidden and output layers, a genetic algorithm with the SigmoidAxon 
transfer function and ConjugateGradient learning rule was employed respectively. 
A maximum of 10,000 epochs were run on NeuroSolutions Version 4.32 
(NeuroDimension Inc., Gainsville, Florida, USA) to ensure optimal training of 
data.  
 
7.2.3 Effect of Active Ingredient on Wafer Properties 
The optimum formulation predicted by NeuroSolutions was prepared and 25mg of 
model drug diphenhydramine HCl (Fnd) was included into the wafer. Responses, 
namely, rate of matrix disintegration, friability and matrix resilience were 
measured and compared to those derived from the same formulation without 
drug (Fn). 
 
7.3 Results and Discussion 
7.3.1 GRG2 Optimisation 
Table 7.2 below shows the formulation variables required to fulfil the desired 
values outlined in Table 7.1, based on the GRG2 algorithm. The desirability is an 
indication as to how achievable the desired response is, 1 being the maximum.  
 
Results generated from the analysis of these wafers are shown in Table 7.3. The 
optimised formulations Fd and Ff were close to their target values. Fr on the other 
hand did not meet its target predicted value of 69.2% resilience. It is seen from 
the data in Table 7.3 that high disintegration values are associated with high 
friability and vice versa. This is undesirable. 
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Table 7.2 Generated values independent variables based on a selected range 
 [HPC] 
(%w/v) 
*Diluent 
Type 
[Diluent] 
(%w/v) 
[Glycine] 
(%w/v) 
Fill 
Volume 
(mL) 
Desirability
Function 
High 10.0 1.00 5.00 0.60 2.00 - 
Low 1.00 0 1.00 0 1.00 - 
Matrix 
Disintegration 
Rate (Fd) 
10.00 0.91 4.98 0.10 2.00 1.00 
Friability (Ff) 1.19 0 4.38 0.60 2.00 1.00 
Matrix 
Resilience 
(Fr) 
1.00 0 5.00 0.00 1.00 1.00 
*Diluent Type: 0=lactose, 1=mannitol and ratios indicate combinations 
 
Table 7.3 Responses measured for formulations optimised using GRG2 ± SD 
(N=3) 
 Fd Ff Fr
Rate of Matrix 
Disintegration (%/s) 
3.89 ± 0.19 
 
0.91 ± 0.05 4.76 ± 0.19 
Friability (% loss) 29.12 ± 0.37 
 
0.45 ± 0.08 
 
9.42 ± 1.96 
 
Matrix Resilience 
(%) 
2.16 ± 0.32 3.70 ± 0.15 
 
3.07 ± 0.44 
 
 
7.3.2 ANN Optimisation 
The gradual levelling of the mean square error (MSE) with standard deviation 
boundaries for the 10 runs, indicating the sequential improvement of model 
predictability is illustrated in Figure 7.2. Table 7.4 reflects the average of the MSE 
values for all the training runs, the best network run out of 10,000 epochs, and 
the overall efficiency of the GFF model in the training process. Overall, it is 
evident that the training model employed was highly efficient. The parameters 
depicted in Table 7.4 are standard statistical indicators used by scientists 
involved in neuro-computing to quantitate the accuracy of model prediction and to 
subsequently select the optimal model (e.g. MLP vs. GFF algorithm). Results 
shown in Table 7.4 are highly satisfactory with a 100% fit for the variables HPC 
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concentration, diluent concentration and fill volume, and correlation coefficients of 
the variables are ≈0.9. 
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Figure 7.2 Average MSE with SD boundaries for 10,000 epochs 
 
The formulation (Fn) determined by the ANN to satisfy the desired properties 
outlined in Table 7.1 was: 
 [HPC] - 10.49 %w/v; 
 Diluent composition – 0.88; 
 [Diluent] – 5.22 %w/v; 
 [Glycine] – 0.006 %w/v; and 
 Fill volume – 0.94 mL.  
 
To test the validity of the ANN an analysis of the responses illustrated that the 
values all fell within the desired range. The matrix disintegration rate was 4.95 
%/s, friability 0 % loss and matrix resilience 11.81%. These results illustrate that 
the ANN was highly efficient in determining an optimised formulation. 
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Table 7.4 Neural Network indicators characterising the efficiency of data training 
Averages of the 
Minimum Training 
Errors 
 
Training Mimimum 
Training Standard 
Deviation 
Average of Minimum 
MSEs 
0.04 0.01 
Average of Final MSEs 0.05 0.01 
Optimal Network Run 
Obtained From Data 
Training 
 
For Desired Responses 
Run Number 
Epoch Number 
Minimum MSE 
Final MSE 
9 
10000 
0.03 
0.03 
Performance of Neural Network by Testing of Training Data 
Performance [HPC] 
(%w/v) 
Diluent 
Composition 
[Diluent] 
(%w/v) 
[Glycine] 
(%w/v) 
Fill 
Volume 
(mL) 
MSE 0.38 0.03 0.41 0.04 0.03 
NMSE 0.03 0.20 0.19 0.73 0.15 
MAE 0.47 0.09 0.39 0.11 0.11 
Min Abs 
Error 
0.001 0.003 0.017 0.001 0.004 
Max Abs 
Error 
1.62 0.15 2.22 0.29 0.43 
Correlation 
coefficient 
0.99 0.98 0.91 0.89 0.93 
Percent 
Correct 
100 No 
Convergence
100 No 
Convergence 
100 
 
7.3.3 Effect of Active Ingredient on Wafer Properties 
It was more difficult to eject the wafers containing drug (Fnd) from the mould. 
Hence, it may be necessary to add more lubricant to this system. The results for 
Fnd are as follows: 
 Matrix Disintegration Rate – 4.95%/s; 
 Friability – 0 % loss; and 
 Resilience – 3.34%.  
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The addition of drug to this system did not affect the disintegration rate, or the 
friability. The matrix resilience was substantially decreased from 11.81% to 
3.35% with the addition of drug. This may be due to the fact that an increase in 
solid powder particles into the system will result in a decrease in the matrix’s 
ability to form pores and hence a decrease in resilience. 
 
7.4 Concluding Remarks 
The statistical approach for formulation optimisation has proved to be useful 
when several variables require simultaneous evaluation. The mathematical 
model generated by regression analysis was used to predict and optimise the 
formulation variables, while the ANN provides an optimised solution. The 
prediction from the model and the experimental results in this study show a 
high degree of correlation, indicating the rigidity of the design employed. 
 
 
 99
Chapter 8      Modification of Wafer Technology to Design a 
Prolonged Release Oramucosal Device: Preliminary Studies 
 
8.1 Introduction 
In this study, a brief investigation was undertaken to modify the wafer technology 
developed thus far in an attempt to prolong the buccal delivery of the bioactive 
agent diphenhydramine hydrochloride. This research was conducted as part of a 
collaboration between The University of the Witwatersrand (South Africa) and 
The Medical University of Gdansk (Poland).  
 
Advantages of prolonged release systems are well known. Briefly these include: 
 Less frequent dosing; 
 Reduced peak to trough fluctuations of drug concentration in the blood; 
 Decrease in side effects; and consequently 
 An increase in patient compliance. 
 
Desirable attributes for prolonged buccal delivery will be a high drug loading 
capacity, ability to regulate drug release, ability to adhere to the buccal mucosa 
and the eventual erosion of the system that will avoid the need to remove the 
device after the dose has been delivered (Martin et al., 2002). These 
requirements can be met by using crosslinked hydrogels, which typically do not 
dissolve on exposure to the medium but rather only absorb saliva. As saliva 
penetrates the hydrogel matrix, chain relaxation occurs and drug is released 
through the spaces and channels within the network as well as through the 
dissolution/ disintegration/ disentanglement of the matrix (Shojaei, 1998). 
Pseudo-hydrogels on the other hand swell, and component molecules leach from 
 100
the surface of the matrix. In this case drug release occurs through the spaces or 
channels within the network as well as through dissolution/disintegration of the 
matrix.  
 
To obtain an extended release buccal system, it is necessary that the system 
remains in contact with the mucosa to facilitate prolonged release. To fulfil this 
requirement, it is compulsory to incorporate a mucoadhesive polymer.  
 
According to Lee and co-workers (2000), mucoadhesion may occur as a result of 
the following forces: 
 Covalent bonding, e.g. cyanoacrylate; 
 Hydrogen bonding, e.g. carbopol®, polycarbophil and acrylates; and 
 Electrostatic interaction e.g. chitosan.  
 
Interactions between chemical entities of the polymer and glycoproteins within 
the mucus or tissue are also responsible for adhesion. Polymer chains with high 
molecular weights and a large number of polar groups tend to develop more 
intensive mucoadhesive bonds. Hydrophilic polymers have stronger bioadhesive 
forces, compared to the hydrophobic components, due to their high swelling 
capacity (Choi and Kim, 2000).  
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8.2 Materials and Methods 
Carmellose (Sol Sodowa, Poland), diphenhydramine hydrochloride (Pliva, 
Krakow, Poland), gelatine (I.G.G., Eberbach, Germany), pectin (Classic Cu 701, 
Herbstreith and Fox, Pforzheim, Germany), and zinc sulphate (Gliwice, Poland) 
were used as received.  
 
8.2.1 Preparation of Prolonged Release Discs for Incorporation into 
Mucoadhesive Polymer 
Crosslinking technology was used to decrease the solubility and hence retard the 
release of active ingredients from a polymeric disc. Zinc ions were used to 
crosslink pectin. This resulted in a three-dimensional network of pectin strands 
held together with ionic interactions. This is commonly described as the egg-box 
model (Grant el al., 1973). A diphenhydramine HCl concentration of 40mg/mL 
was achieved by mixing the drug in a 2%w/v solution of pectin in deionised water. 
Blisters (15mm diameter), were filled with 0.5mL of the suspension, frozen and 
then crosslinked. The polymer was frozen to ensure that the disc shape was 
maintained. Three methods of crosslinking were investigated: 
 Method I: 0.5mL of 2.5%w/v zinc sulphate (ZnSO4) solution was placed on 
the surface of the disc, and allowed to cure for 1 hour. Thereafter, the 
excess ZnSO4 solution was removed by decanting. The discs lyophilised. 
Table 8.1 depicts the conditions of freeze dryer (Alpha 2-4, Christ, 
Osterode am Harz, Germany); 
 Method II: The ZnSO4 solution was applied to the surface of the frozen 
discs in the form of a spray and refrozen. Once frozen, the discs were 
turned and the procedure was repeated on the other side. These discs 
were frozen and then lyophilised; and 
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 Method III: Discs were frozen in liquid nitrogen, then transferred to blisters 
with a diameter of 20mm. 0.5mL of the ZnSO4 solution was added to the 
discs and allowed to cure for 24 hours. Thereafter the ZnSO4 salt solution 
was removed, discs were then lyophilised. 
 
Table 8.1 Conditions and parameters of lyophilisation 
Step Shelf temperature (ºC) Time (hours) Vacuum (mbar)
1. Freezing - 40 1 - 
2. Primary drying - 40 2 0.08  
 -20 5  
 0 14  
 +20 4  
3. Secondary 
drying +35 2 0.08 
 
8.2.2 Incorporation of Crosslinked Granules into Mucoadhesive Wafer 
System 
Discs were placed in wells containing 0.5mL of the mucoadhesive agent 
composed of 2%w/v pectin, 2%w/v carmellose sodium and 2%w/v gelatine 
(PCG), and frozen. A further 1mL of PCG was added and subjected to 
lyophilisation.  
 
8.2.3 Preparation of Prolonged Release Granules for Incorporation into 
Mucoadhesive Polymer 
During preliminary experimentation, an optimal composition of granules was 
determined to be 10g diphenhydramine, 10g pectin, 33.3g water, and 33.3g of 
20% w/v ZnSO4 solution. 
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Diphenhydramine HCl and pectin were manually mixed together with a mortar 
and pestle. Water was added in a dropwise manner to allow for the polymer to 
swell. The ZnSO4 was added, causing the mixture to form a firm gel-like mass as 
a result of the crosslinks formed. The gel mass was extruded through stainless 
steel meshes of pore size: 0.1mm, 0.2mm and 1.0mm, forming granules that 
were dried at 37°C in an oven (Memmert, Bavaria, Germany).  
 
To determine the drug entrapment efficiency of the granules, accurately weighed 
samples were dissolved in 10mL of a 2%w/v sodium citrate solution. Samples 
(N=3-5) were diluted with water and analysed using UV spectroscopy at a 
wavelength of 310nm. 
 
8.2.4 Release Profile of Prolonged Release Discs and Granules 
Discs or granules were placed in a beaker with 10mL of deionised water. The 
beaker was sealed using parafilm, and placed in a water bath set on very slow 
movement (110cpm) at a temperature of 37˚C. Samples were drawn after 30 
minutes, 60 minutes and hourly thereafter.  
 
8.2.5 Incorporation of Crosslinked Granules into Mucoadhesive Wafer 
System 
Granules, were suspended in PCG, frozen and then lyophilised. Granules of 
diameter 0.2mm and 1.0mm were selected based on their release profiles for the 
production of wafers and will be termed W2 and W3 respectively from here on. For 
comparative purposes, an equivalent amount of diphenhydramine HCl was 
suspended in PCG, this suspension was used to prepare lyophilised wafers 
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termed W1. The theoretical amount of drug present in each of the wafers was 
20mg. To simulate the mechanical pressure and wetting of the system that 
occurs when the patient applies the wafer to the buccal region, wafers W1 and W3 
were wet and a 200g weight was applied to them (W1p and W3p respectively). 
Release profiles were characterised as described in this Chapter, section 8.3.4 
The portion of the system remaining intact after 24 hours was dissolved in a 
2%w/v sodium citrate solution. 
 
8.3 Results and Discussion 
8.3.1 Prolonged Release Discs for Incorporation into Mucoadhesive 
Polymer 
Discs prepared by the methods described in this Chapter, section 8.3.1 were 
easily removed from the blisters. Although all the discs had a porous surface, the 
discs prepared by methods I and II maintained the shape of the blister while 
those prepared by method III appeared flatter and harder as observed in Figure 
8.1(c). 
 
 
Figure 8.1 Lyophilised discs of pectin containing diphenhydramine HCl 
crosslinked using ZnSO4 solution using method: (a) moistening, (b) spraying and 
(c) immersion 
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8.3.2  Drug Release Profiles 
The release of diphenhydramine HCl from discs prepared using methods I and II 
was rapid (Figure 8.2), samples were withdrawn until no further changes were 
observed in the drug concentration liberated. The rapid liberation of the drug was 
due to incomplete crosslinking as a result of insufficient curing time. A cross-
section of the discs showed that only the surface of the discs had been 
crosslinked. Drug release from the discs manufactured according to method III 
was satisfactory (Figure 8.2), however due to the change in shape, they were 
discarded from further studies.  
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Figure 8.2 Release profiles of diphenhydramine HCl discs prepared by method I, 
II and III 
 
A cross-section of the wafers was taken using a scalpel, showing that the discs 
did not change location during freezing or lyophilisation, thus remaining the 
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centre layer of the wafer as positioned at the onset as the middle layer of the 
wafer. Due to the presence of Zn2+ ions on the surface of the discs, crosslinks 
occurred with pectin present in the PCG mixture allowing firm attachment of the 
discs to the mucoadhesive.  
 
8.3.3 Drug Release Profiles of Granules 
It was found that the drug entrapment of the granules was ≈90% of the theoretical 
value. During the characterisation of the release profile of the granules, it was 
noted that after 24 hours, granules did not dissolve completely, therefore the 
remaining granules were dissolved in a 2%w/v sodium citrate solution to 
determine the amount of drug remaining. Similar release profiles (Figure 8.3) 
were observed for the 0.2mm and 1.0mm granules, with ≈50% of the active 
released at 3 hours and ≈70% after 5 hours. The smallest granules released 
diphenhydramine HCl very rapidly liberating close to 50% of its load within the 
first hour (Figure 8.3).  
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Figure 8.3 Drug release profiles of crosslinked granules varying in size (N =3-5) 
 
8.3.4 Incorporation of Crosslinked Granules into the Mucoadhesive Wafer 
System 
According to a study conducted by Romanowski (2004), a mixture composed of 
2%w/v pectin, 2%w/v carmellose sodium and 2%w/v gelatine provided 
satisfactory mucoadhesion. This polymer mixture was used as the mucoadhesive 
base throughout this study. 
 
The mucoadhesive polymer PCG, would ensure adherence of the system to the 
buccal mucosa, while the crosslinked granules provide prolonged release of the 
drug. Based on the successful slow release profiles of the 0.2mm and 1.0mm 
granules (Figure 8.3), these were selected for introduction into the wafer system. 
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The wafers that were produced had the following properties, as determined by 
visual inspection: 
 Good mechanical strength; 
 Porous; and 
 Ease of removal from moulds. 
The W2 and W3 systems had granules suspended throughout the matrix which 
appeared denser on the surface of the wafers as compared to those within the 
system. This was observed from cross-sections of the samples.  
 
As a result of the pressure applied to formulations W1p and W3p, the wafer 
decreased to half of its original height, thus reducing the diffusion path for the 
drug. As a result of this phenomenon, it was anticipated that the drug would be 
liberated faster from these samples.  
 
8.3.4.1 Drug Release Profiles  
The inclusion of the granules to the wafer system retarded the release of 
diphenhydramine HCl even further. In the pure granule form, the 0.2mm and 
1.0mm granules released ≈60% of the active (Figure 8.3), while the wafer system 
W2 and W3 containing the granules had only liberated 48% and 24% of drug 
respectively (Figure 8.4). Disintegration of the W2 system was observed. This 
could be responsible for the similarity of this release profile with that of W1 
wafers. These wafers released diphenhydramine HCl the fastest among the 
unpressed wafers, while the pressed form (W1p) provided the quickest release of 
the drug as compared to pressed and unpressed wafers. In contrast to this, the 
release profile of the W3p wafers was similar to the W3 wafers, indicating that the 
crosslinked granules within the system do control drug release.  
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Figure 8.4 Percentage release of various diphenhydramine wafers intended for 
prolonged release (Wafers containing: only drug – W1, granules of 0.2mm 
diameter – W2, 1.0mm diameter granules – W3. The subscript p indicates that 
pressure has been applied to these wafers) 
 
8.4 Concluding Remarks 
The preliminary studies into the development of these prolonged release wafers 
seem to be promising, indicating the feasibility of producing such a system. 
However refinement of the system is necessary. Further studies in the 
formulation of smaller granules, as well as modification of the crosslinking 
techniques will be essential. Combining crosslinking as well as dispersing pure 
drug within the matrix may be an approach to achieve the desired release 
profiles.  
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Chapter 9      Conclusions and Recommendations 
 
9.1 Conclusions 
The lyophilised wafer developed throughout this research is an effective and 
versatile drug delivery system for oramucosal application. This has been 
established from the extensive physicochemical and physicomechanical profiling 
conducted. 
 
Through a screening and selection of polymers, HPC had the lowest gelation 
characteristics and was therefore suitable for the development of the wafer 
system. Suitable excipient and polymer combinations were established which 
allowed for the development of rapidly disintegrating and prolonged release wafer 
systems. The wafer system containing HPC, lactose, mannitol and glycine had 
the ability to disintegrate within 30 seconds. The modified wafer system, 
consisting of pectin crosslinked with zinc ions serving as the drug reservoir, and 
mucoadhesive polymer combination of pectin, carmellose and gelatine, provided 
effective release of model drug diphenhydramine hydrochloride over 
approximately six hours.  
 
A successful, reproducible, manufacturing technique was established by the 
optimisation of the lyophilisation cycle, employing mineral oil as a lubricant and 
polystyrene moulds providing wafers of suitable characteristics. 
 
Characteristics that were critical to the mechanistic functioning of the wafer, such 
as rate of matrix disintegration, rate of simulated saliva influx and friability, were 
extensively elucidated to determine the effects of the formulation variables using 
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ANOVA technology. A low concentration of polymer was associated with a high 
disintegration rate, friability and influx of simulated saliva. As predicted, an 
increase in the amount of diluent present increased both the disintegration rate 
and friability.  
 
The ANOVA method was used to present a comprehensive profile of the 
physicomechanical properties such as matrix yield value, matrix tolerance, matrix 
absorption energy, matrix resilience and Brinell hardness number. A firm 
understanding of the effects of formulation variables on the responses formed the 
corner stone of the optimisation process. 
 
Although the DSC did not form a component of the optimisation process, the 
information provided was integral in the determination of the effect of 
lyophilisation on the native ingredients. Through this analytical process, it was 
accepted that lyophilisation did not significantly alter the Tg. 
 
The aim of this study, to consider formulation variables in the statistical 
optimisation of the lyophilised wafer system was achieved. The Design of 
Experiments and Artificial Neural Networks proved to be highly effective tools for 
the optimisation process, ultimately producing formulation characteristics within 
the desired range, disintegration 1-6 %/s, friability 0-0.8% weight loss and 
maximum resilience. 
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9.2 Future Prospects and Challenges 
Whilst this study was successful with the use of diphenhydramine hydrochloride 
as the model drug, the compatibility of the wafer matrix with other drug classes 
would necessitate further studies.   
 
Most commercially available rapidly dissolving open matrix systems facilitate 
rapid disintegration, most of the drug is absorbed via the GIT. The extent of 
penetration of drug through the buccal mucosa of the system developed in this 
study may be evaluated using in situ permeation studies in the pig model. The 
efficiency of drug absorption through the membrane may be increased with the 
inclusion of permeation enhancers in the formulation. 
 
Thus far this study has supplied extensive data on the in vitro characterisation of 
the matrices. As in vivo studies provide valuable information relating to the 
disintegration and mechanical properties of the matrices, it may not completely 
mimic in vitro studies completely. In vivo studies should be performed, initially in 
animal models, followed by those in healthy human volunteers, to obtain the 
pharmacokinetic parameters. It will also be useful to develop an in vitro-in vivo 
correlation (IVIVC). 
 
In addition, due to the well known fragility and hygroscopicity of lyophilised 
products, an appropriate packaging system for the wafers need to be developed 
to ensure that the dosage form reaches the patient and is administered intact. 
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The modification of this technology to provide a prolonged release mucoadhesive 
system seems promising. It is envisaged that this system will be applicable to 
many drugs requiring the extended release of bioactive material. 
 
Therefore, the lyophilised wafer matrices developed in this study are highly 
effective in the rapid delivery of drugs, using the oral route as a site of 
administration. The manufacturing process is simple and reproducible. A number 
of unique opportunities are presented for the formulation of a controlled release 
drug delivery system. 
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